

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/009344

International filing date: 22 March 2005 (22.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/554,994
Filing date: 22 March 2004 (22.03.2004)

Date of receipt at the International Bureau: 25 April 2005 (25.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

149551



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 18, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/554,994

FILING DATE: *March 22, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/09344



Certified by

Don W. Dudas

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR 1.53 (c).

INVENTOR(S)				
Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)		
Joseph J. Sergei A.	BARCHI, Jr. SVAROVSKY	Frederick, Maryland Frederick, Maryland		
<input type="checkbox"/> Additional inventors are being named on the second separately numbered sheets attached hereto				
TITLE OF THE INVENTION (280 characters max)				
CARBOHYDRATE-ENCAPSULATED QUANTUM DOTS FOR BIOLOGICAL IMAGING				
CORRESPONDENCE ADDRESS				
Direct all correspondence to:		*26694*		
<input checked="" type="checkbox"/> Customer Number	26694	PATENT TRADEMARK OFFICE		
OR	Type Customer Number here			
<input checked="" type="checkbox"/> Firm or Individual Name	VENABLE			
Address	P.O. Box 34385			
Address				
City	Washington	State	DC	ZIP 20043-9998
Country	U.S.A.	Telephone	202-334-4000	Fax 202-344-8300
ENCLOSED APPLICATION PARTS (check all that apply)				
<input checked="" type="checkbox"/> Specification Number of Pages	137	<input type="checkbox"/> CD(s), Number		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	5	<input type="checkbox"/> Other (specify)		
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)				
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees				
FILING FEE AMOUNT (\$)				
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 22-0261 \$160.00				
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.				
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.				
<input type="checkbox"/> No.				
<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: Dept. of Health and Human Services.				

Respectfully submitted,
SIGNATURE

Date

3/22/2004

TYPED OR PRINTED NAME Michael A. Gollin

REGISTRATION NO. 31,957
(if appropriate)

Docket Number: 31978-201280

TELEPHONE 202-344-4072

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51, and is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

**CARBOHYDRATE-ENCAPSULATED QUANTUM DOTS FOR
BIOLOGICAL IMAGING**

This application is related to international application number PCT/US2003/034897, filed November 5, 2003, which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

[0001] The present invention relates to biofunctionalized quantum dots, which can be used, for example, in biological research, medical research, medical imaging, and medical therapy.

[0002] Quantum dots are small semiconductor particles that exhibit quantum confinement. See "Overview," Quantum Dot Corp., (2003) <http://www.qdots.com/new/technology/overview.html>. A semiconductor has a characteristic band gap, which is the difference in energy between an electron in the valence band and an electron in the conduction band of the semiconductor material. When energy is applied to the material, for example in the form of a photon having a quantum of energy greater than or equal to the band gap, an electron can be stimulated to jump from the valence band to the conduction band. The missing electron in the valence band is referred to as a "hole". See H.B. Gray, "Chemical Bonds," (W.A. Benjamin, Inc., 1973), pp. 208-218. When an electron falls back into a "hole" in the valence band, a photon having a quantum of energy equal to the band gap, and thus a particular wavelength, can be emitted.



Thus, materials in which high energy photons can cause electrons to jump into the conduction band, after which electrons can fall back into the valence band, emitting a photon, can exhibit the phenomenon of fluorescence. See A.E. Siegman, "Lasers," University Science Books, 1986), pp. 6-15.

[0003] Quantum confinement refers to a phenomenon observed when the physical size of the semiconductor is smaller than the typical radius of the electron-hole pair (Bohr radius). In this case, the wavelength of light emitted through electron-hole recombination is shorter than the wavelength of light emitted by the semiconductor in bulk. The wavelength of light emitted by a semiconductor exhibiting quantum confinement can be termed the characteristic wavelength. Quantum dots can be made to fluoresce at their characteristic wavelength by exposing them to light having a wavelength shorter than the characteristic wavelength. The wavelength of light emitted is dependent on the size of the quantum dot: a smaller size results in a shorter wavelength. Therefore, the characteristic wavelength of a quantum dot can be "tuned" by adjusting the size of the quantum dot. Furthermore, techniques exist for producing quantum dots with narrow monodispersity in size, so that the light emitted from a number of quantum dots has a narrow bandwidth. See "Overview," Quantum Dot Corp., (2003) <http://www.qdots.com/new/technology/overview.html>.

[0004] The essential part of a quantum dot is a nanocrystalline core, a semiconductor in a crystalline state which has a characteristic size of from about 1 to about 100 nm. Quantum dots used for their fluorescing properties can have a size range of from about 1 to about 10 nm. See "Anatomy", Quantum Dot Corp., (2003) <http://www.qdots.com/new/technology/dottech.html>.

[0005] The quantum efficiency refers to the ratio of the number of photons

emitted to the number of photons to which the quantum dot is exposed and which stimulate light emission.

[0006] To increase the quantum efficiency of a nanocrystalline core, and thereby enhance the intensity of fluorescence, the nanocrystalline core can be overcoated with a shell layer of a semiconductor material which has a band gap greater than the band gap of the nanocrystalline core. Bawendi et al, U.S. Patent 6,306,610. A shell layer can also serve to protect the nanocrystalline core from the surrounding environment. If protection of the nanocrystalline core from the environment is important, but enhancement of quantum efficiency is not, a non-semiconductor material can be used for the shell layer. A quantum dot having both a nanocrystalline core and a shell layer can be referred to as a core/shell quantum dot.

[0007] Chemical groups, including chemical groups which have an effect on a biological system, can be bound to the surface of a nanocrystalline core or a shell of a quantum dot. This capacity to be functionalized, together with chemical stability and tunable fluorescing properties, makes quantum dots of great interest in the development of new materials and techniques for biological research and medical diagnosis. Furthermore, quantum dots are much less prone to photobleaching than many conventional dyes.

[0008] For most biological or medical applications, in order to be useful, a nanocrystalline core or a shell of a quantum dot must be rendered hydrophilic and have a biofunctional group attached to its surface. Chan and Nie linked mercaptoacetic acid to cadmium selenide core/ zinc sulfide shell quantum dots. They bonded the protein transferrin to the linked mercaptoacetic acid groups by using ethyl-3-(dimethylaminopropyl) carbodiimide. Chan and Nie found that the

transferrin linked to the quantum dot was recognized by receptors on a cell surface. See Chan and Nie, "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection", *Science*, v. 281 (1998) p. 2016.

[0009] Akerman et al. used cadmium selenide core/ zinc sulfide shell quantum dots coated with trioctylphosphine (TOPO), rendered them water soluble, and coated them with mercaptoacetic acid. Thiolated peptides were then linked to the surface, i.e., to the surface of the shell, of the quantum dots. Akerman et al. also made quantum dots in which thiolated polyethylene glycol and thiolated peptides were linked to mercaptoacetic acid coated quantum dots. They found that the peptide-functionalized quantum dots coupled with corresponding peptide receptors expressed by cells. See Akerman et al., "Nanocrystal targeting in vivo", *Proc. National Academy of Sciences*, v. 99(2) (2002) p. 12617.

[0010] Larson et al. encapsulated a cadmium selenide core/ zinc sulfide shell quantum dot within a amphiphilic polymer to render the quantum dot hydrophilic. They were able to image fluorescing quantum dots through the skin. Larson et al. suggested that the cadmium selenide core/ zinc sulfide shell quantum dots leave the body before breakdown because there were no noticed toxic effects from the cadmium on mice into which they were injected. See Larson et al., "Water-Soluble Quantum Dots for Multiphoton Fluorescence Imaging in Vivo", *Science*, v. 300 (2003) p. 1434.

[0011] Semiconductor nanocrystals can attach trioctylphosphine oxide (TOPO) as a ligand, rendering the semiconductor nanocrystals soluble in organic solvents such as chloroform and toluene, but not soluble in polar solvents such as water and ethanol. In an approach, a cadmium selenide core/zinc sulfide shell

quantum dot was first coordinated with TOPO. Molecules in which mannose groups were covalently bonded to a phosphine oxide were then used to replace the TOPO groups on the cadmium selenide core/zinc sulfide shell, rendering the quantum dot hydrophilic. See Tamura et al., "Synthesis of Hydrophilic Ultrafine Nanoparticles Coordinated with Carbohydrate Cluster", *J. Carbohydrate Chemistry*, v. 21(5) (2002) p. 445. However, it is doubtful whether the functionalized quantum dots produced were stable. In another approach, cadmium selenide core/ zinc sulfide shell structures coordinated with TOPO were treated with a silathiane and mercaptosuccinic acid. The quantum dots were treated with a solutions of carboxymethyl dextran and of polylysine and treated with 1-ethyl-3-(3)-dimethylaminopropyl carbodiimide, which acts as a crosslinking agent. See Chen et al., "Synthesis of Glyconanospheres Containing Luminescent CdSe-ZnS Quantum Dots", *Nano Letters*, v. 3(5) (2003) p581.

[0012] The applicants attempted to displace a TOPO layer on a cadmium selenide core/ zinc sulfide shell quantum dot commercially available from Evident Technologies with a hydrophilic thiol compound using the modified phase-transfer procedure developed by Wang et al. See Wang et al., *J. Am. Chem. Soc.*, v. 106 (2002) p. 2293. However, either the displacement was incomplete or the resultant functionalized quantum dots were fragile and did not survive mild ultrafiltration or dialysis and precipitated or flocculated shortly after the hydrophilic thiol compound was removed from the solution.

[0013] Bawendi et al. functionalized quantum dots with proteins and with oligonucleotides. The procedure used started with TOPO-capped cadmium selenide core/ zinc sulfide shell quantum dots with which the proteins or oligonucleotides were linked. Bawendi et al., U.S. Patent No. 6,306,610.

[0014] Gaponik et al. synthesized hydrophilic cadmium telluride core/cadmium sulfide shell quantum dots using an aqueous synthesis approach. In the approach, a cadmium salt and a mercapto-compound were mixed in an aqueous solution through which hydrogen telluride was bubbled. Cadmium telluride nanocrystals were formed which were capped at the nanocrystal surface with the mercapto compound. The mercapto compound was linked to the cadmium telluride core through the sulfur atom. Thus, the cadmium telluride core was understood to be surrounded by a layer of sulfur atoms, which also were present deeper in the core, and which bonded to the cadmium atoms to form a cadmium sulfide shell layer. The hydrophilic cadmium telluride core/cadmium sulfide shell quantum dots exhibited good photostability; i.e., fluoresced over a long duration of illumination. Gaponik et al., "Thiol-Capping of CdTe Nanocrystals: An alternative to Organometallic Synthetic Routes", *J. Phys. Chem. B*, v. 106 (2002) p. 7177.

[0015] For a preparation of quantum dots with biofunctional groups linked to the surface of a nanocrystalline core or a shell of a quantum dot to be useful in biological research, medical diagnostic, and medical therapeutic applications, the quantum dots must fluoresce brightly, be hydrophilic, and be stable in water not containing excess biofunctional groups for prolonged periods of time.

[0016] Coupling of receptors to cell-surface saccharides mediates many relevant biological processes, including differentiation, motility, adhesion, tumor progression, and metastasis. Therefore, quantum dots functionalized with saccharides are of interest for biological research, medical diagnostic, and medical therapeutic applications. However, quantum dots suitable for such applications have up until now not been developed.

[0017] There thus remains a need for quantum dots which fluoresce brightly, have biofunctional groups linked to the surface of a nanocrystalline core or a shell, are hydrophilic, and are stable in aqueous solution. There is also a continuing need for quantum dots which have saccharides linked to the surface of a nanocrystalline core or a shell.

SUMMARY OF THE INVENTION

[0018] It is therefore an object of the present invention to provide novel biofunctionalized quantum dots which fluoresce brightly, are hydrophilic, and are stable in aqueous solution. It is further an object of the present invention to provide quantum dots which have saccharides linked to the surface of a nanocrystalline core or a shell.

[0019] An embodiment of a biofunctionalized quantum dot according to the invention includes a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface, a mercaptoalkanoic acid linked to the surface, and a biofunctional group linked to the surface. The ratio of mercaptoalkanoic acid molecules to biofunctional group molecules linked to the surface can be in the range of from about 1:1 to about 5:1. The mercaptoalkanoic acid can be chosen from a set of mercaptoalkanoic acids not including mercaptosuccinic acid. The mercaptoalkanoic acid can be chosen to have only one carboxyl group and comprising less than seven carbon atoms. The mercaptoalkanoic acid can be mercaptoacetic acid.

[0020] In an embodiment, the biofunctional group is chosen to have a molecular weight greater than a molecular weight of the mercaptoalkanoic acid. The biofunctional group can be chosen to have a molecular volume greater than a molecular volume of the mercaptoalkanoic acid.

[0021] In another embodiment of a biofunctionalized quantum dot according to the invention, a shell layer overcoats a nanocrystalline core. The shell layer can include cadmium sulfide and the nanocrystalline core can include cadmium telluride, cadmium selenide, mercury telluride, and mercury selenide.

[0022] The biofunctional group on a quantum dot according to the invention can be a saccharide. For example, the saccharide can be a tumor-associated carbohydrate antigen. The saccharide can be Thomsen-Friedenreich (Tf) disaccharide. The biofunctional group on a quantum dot according to the invention can be chosen from a set of saccharides not comprising mannose or dextran. The saccharide can be directly linked to a sulfur atom, the sulfur atom being linked to the surface of the nanocrystalline core. The saccharide can be linked to a linking group, the linking group linked to a sulfur atom, and the sulfur atom linked to the surface of the nanocrystalline core. The linking group can include a carbon atom.

[0023] In another embodiment, the biofunctionalized quantum dot is stable in aqueous solution under storage in the dark at 4 °C for at least 4 months with respect to luminescence, precipitation, flocculation, and leaching of the biofunctional group.

[0024] In an embodiment, a formulation includes a liquid, a biofunctionalized quantum dot, a mercaptoalkanoic acid linked to the surface of the nanocrystalline core of the quantum dot, and a biofunctional group linked to the surface and the biofunctionalized quantum dot is dissolved or suspended in the liquid and does not precipitate or flocculate.


[0025] In an embodiment, a biofunctionalized quantum dot is made by refluxing a biofunctional group-thiol of Formula III with a cadmium salt, hydrogen-alkali-telluride or hydrogen-alkali-selenide, and a suitable solvent to produce a quantum dot in a solution. The R₁ group includes at least one carbon atom. Suitable solvents include water and N,N-dimethylformamide (DMF). The refluxing can be conducted in a range of from about 24 to about 48 hours. The

refluxed mixture can further include a mercaptoalkanoic acid, for example, mercaptoacetic acid. The biofunctional group can be a saccharide, for example, Thomsen-Friedenreich disaccharide. The refluxing can be carried out with Thomsen-Friedenreich disaccharide and mercaptoacetic acid in a molar ratio of from about 1:1 to about 5:1. After refluxing, the solution can be purified and dried to obtain a biofunctionalized quantum dot preparation. The purifying can include separating the biofunctionalized quantum dot from the remainder of the solution by filtration through an ultrafiltration membrane with a cutoff of about 50 kilodaltons. The purified and dried biofunctionalized quantum dot preparation can be dissolved or suspended in an aqueous solvent.



III

[0026] A biofunctional group-thiol of Formula III can be made by reacting a glycoside of Formula I with an alkylthio acid in the presence of a catalyst to produce a thioester of Formula II, debenzylidenating the thioester of Formula II, and hydrolyzing the thioester of Formula II to produce the biofunctional group-thiol of Formula III; the group R_2 includes at least one carbon atom.




I




II


[0027] In an embodiment, a biofunctionalized quantum dot is made as follows. A glycoside of Formula IV is reacted with an alkylthio acid in the presence of 2,2'-azobisisobutyronitrile in 1,4-dioxane at about 75 °C to produce a thioester of Formula V, debenzylidinating the thioester of Formula V. The thioester of Formula V is debenzylidinated and the debenzylidinated thioester of Formula V is hydrolyzed to produce a Thomsen-Friedenreich-thiol of Formula VI. The Thomsen-Friedenreich-thiol of Formula VI is refluxed with cadmium perchlorate, mercaptoacetic acid, hydrogen sodium telluride, and a suitable solvent, either water or N,N-dimethylformamide, to produce a Thomsen-Friedenreich-functionalized quantum dot in a solution.



IV




V



VI

[0028] The debenzylidination step can include treating the thioester of Formula V with aqueous acetic acid at about 60 °C and evaporating to obtain the debenzylidinated thioester. Alternatively, the debenzylidination step can include treating the thioester of Formula V with acetyl chloride in methanol, adding pyridine to the thioester of Formula V with acetyl chloride in methanol for quenching the reaction, and evaporating to obtain debenzylidinated thioester. The hydrolyzing step can include treating the debenzylidinated thioester with sodium methoxide in methanol to produce the Thomsen-Friedenreich-thiol of

Formula VI. Alternatively, the hydrolyzing step can include treating the debenzylidinated thioester with sodium methoxide in methanol while bubbling air through the debenzylidinated thioester, sodium methoxide, and methanol to produce a Thomsen-Friedenreich-disulfide of Formula VII and treating the Thomsen-Friedenreich-disulfide of Formula VII with dithiothreitol in water to produce the Thomsen-Friedenreich-thiol of Formula VI.



VII

[0029] In an embodiment, a biofunctionalized quantum dot is used for imaging. The biofunctionalized quantum dot, of which the biofunctional group includes a saccharide, or which includes a mercaptoalkanoic acid linked to the nanocrystalline surface, is contacted with a biological material. The biological material is exposed to light having a wavelength effective to cause the quantum dot to fluoresce and the fluorescing quantum dots are imaged. The biofunctional group can be Thomsen-Friedenreich disaccharide. The biological material can include a cell culture or can include a tissue. The biofunctionalized quantum dot can be dissolved or suspended in a biocompatible aqueous solvent. Contacting the

biofunctionalized quantum dot with biological material can included injecting the biofunctionalized quantum dot into tissues of a living animal.

[0030] The fluorescing quantum dot adhered to a secretion of a biological material can be imaged. Tissue which imaging identifies as tissue to which the biofunctional group exhibits high affinity can be identified as tissue in a diseased or abnormal state, for example, a cancerous state.

[0031] In an embodiment, several types of biofunctionalized quantum dots are used for imaging. The biofunctional groups of the biofunctionalized quantum dots include a saccharide, or the biofunctionalized quantum dots include a mercaptoalkanoic acid linked to the nanocrystalline surface. Each type of biofunctionalized quantum dot has a characteristic wavelength distinct from the other types. Each type of quantum dot is functionalized with a different antigen or a different set of antigens. The several types of biofunctionalized quantum dots are contacted with a biological material, the biological material is exposed to light having a wavelength effective to cause the quantum dots to fluoresce, and the fluorescing quantum dots are imaged.

[0032] In an embodiment, a biofunctionalized quantum dot is used for therapy. The biofunctional group of the biofunctionalized quantum dot includes a saccharide, or the biofunctionalized quantum dot includes a mercaptoalkanoic acid linked to the nanocrystalline surface. The biofunctionalized quantum dot is contacted with a biological material and thereby treats a disease. The biofunctional group can be an immune-response-stimulating group. The biofunctional group can be a tumor-associated antigen. The biofunctional group can be Thomsen-Friedenreich disaccharide. The contacting with a biological material can include injecting the biofunctionalized quantum dot into tissues of a

living animal in order to treat cancer.

[0033] A biofunctionalized quantum dot used for therapy can have a therapeutic agent linked to the surface. The shell layer or the nanocrystalline shell of a biofunctionalized quantum dot used for therapy can include a therapeutic agent.

[0034] In an embodiment, a biofunctionalized quantum dot is used to coat a device which, when not coated, is in contact with a biological material. The biofunctional group of the biofunctionalized quantum dot includes a saccharide, or the biofunctionalized quantum dot includes a mercaptoalkanoic acid linked to the nanocrystalline surface.

[0035] In an embodiment, a cell-quantum dot complex includes a biofunctionalized quantum dot linked to a cell. The biofunctional group of the biofunctionalized quantum dot includes a saccharide, or the biofunctionalized quantum dot includes a mercaptoalkanoic acid linked to the nanocrystalline surface. The biofunctional group can be Thomsen-Friedenreich disaccharide.

BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 is a schematic of cadmium telluride nanocrystal functionalized with mercaptoacetic acid and with a biofunctional group-thiol.

[0037] Figure 2 is a graph of the absorption spectra of growing Thomsen-Friedenreich-functionalized cadmium telluride quantum dots at different times.

[0038] Figure 3 shows the NMR spectra of a Thomsen-Friedenreich-thiol and of Thomsen-Friedenreich-functionalized cadmium telluride quantum dots.

[0039] Figure 4 shows the NMR spectra of mercaptoacetic acid, of a Thomsen-Friedenreich-thiol, and of Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots.

[0040] Figure 5 shows the absorption spectrum of Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots.

DETAILED DESCRIPTION

[0041] Embodiments of the invention are discussed in detail below. In describing embodiments, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. A person skilled in the relevant art will recognize that other equivalent components can be employed and other methods developed without parting from the spirit and scope of the invention. All references cited herein are incorporated by reference as if each had been individually incorporated.

[0042] In an embodiment of a biofunctionalized quantum dot, a biofunctional group is linked to the surface of a nanocrystalline core exhibiting quantum confinement. Examples of core materials included in the nanocrystalline core include zinc sulfide, zinc selenide, zinc telluride, cadmium sulfide, cadmium selenide, cadmium telluride, mercury sulfide, mercury selenide, mercury telluride, magnesium telluride, aluminum phosphide, aluminum arsenide, aluminum antimonide, gallium nitride, gallium phosphide, gallium arsenide, gallium antimonide, indium nitride, indium phosphide, indium arsenide, indium antimonide, aluminum sulfide, lead sulfide, lead selenide, germanium, or silicon. Core materials also include other group II – group VI compounds, group III – group V compounds, and group IV compounds. Core materials also include other semiconductor materials. The core material may also be formed of an alloy, compound, or mixture of these compounds and elements which are suitable core materials. For example, the core material can be a mercury-cadmium sulfide compound. The core material can also be doped with one or more suitable dopants.

[0043] In an embodiment, a biofunctionalized quantum dot includes a

shell layer overcoating and surrounding a nanocrystalline core. The shell layer can include a single layer of a shell material different from the core material which forms the nanocrystalline core. The shell layer can include a semiconductor material with a band gap greater than the band gap of the nanocrystalline core. Examples of shell materials included in the shell layer include zinc oxide, zinc sulfide, zinc selenide, zinc telluride, cadmium oxide, cadmium sulfide, cadmium selenide, cadmium telluride, mercury oxide, mercury sulfide, mercury selenide, mercury telluride, magnesium telluride, aluminum nitride, aluminum phosphide, aluminum arsenide, aluminum antimonide, gallium nitride, gallium phosphide, gallium arsenide, gallium antimonide, indium nitride, indium phosphide, indium arsenide, indium antimonide, aluminum sulfide, lead sulfide, lead selenide, germanium, or silicon. Shell materials also include other group II – group VI compounds, group III – group V compounds, and group IV compounds. Shell materials also include other semiconductor materials. The shell material may also be formed of an alloy, compound, or mixture of these compounds and elements which are suitable shell materials. The term quantum dot may refer to a nanocrystalline core without a shell layer, or a to the composite structure of a nanocrystalline core with a shell layer. The core material can also be doped with one or more suitable dopants.

[0044] A shell layer can include a single layer of the atoms which form the shell material. For example, a cadmium selenide or cadmium telluride nanocrystalline core can be overcoated with a cadmium sulfide shell. The cadmium sulfide shell can be formed of sulfur atoms bonded to cadmium atoms on the surface of or within the cadmium selenide or cadmium telluride nanocrystalline core. As another example, a mercury selenide or mercury

telluride nanocrystalline core can be overcoated with a mercury sulfide shell. The mercury sulfide shell can be formed of sulfur atoms bonded to mercury atoms on the surface of or within the mercury selenide or mercury telluride nanocrystalline core.

[0045] A quantum dot is biofunctionalized when the quantum dot has biofunctional groups linked to the surface of a nanocrystalline core or a shell which can act to change the response of a biological system from that resulting from contact with a non-functionalized nanocrystalline core or shell. The term "link" refers to an attractive association of an atom or molecule with another atom or molecule, for example, a covalent bond, an ionic bond, a hydrogen bond, or a bond or interaction of another type. As an example, biofunctional groups may be attached to the surface of a nanocrystalline core or a shell which stimulate an immunological response, allow the quantum dot as a whole to adhere to biological material, and render the quantum dot as a whole biologically inert so that the biological system does not "see" the quantum dot and does not respond to the quantum dot. A biological material can include a secretion, e.g., an antibody, from another biological material. A biofunctional group which stimulates an immunological response can be referred to as an immune-response-stimulating group.

[0046] In the context of interactions with biological entities, such as cells, or chemical constituents thereof, e.g., receptors, the term "binding" is used consistently with usage in the biological literature. That is, "binding" can refer to the net attractive force between two molecules or macromolecular structures resulting from a number of different, simultaneously acting types of bonds including ionic bonds, hydrogen bonds, and van der Waals interactions.

[0047] In another embodiment, a biofunctional group is linked to the surface of a nanocrystalline core and a mercaptoalkanoic acid is linked to the surface of the nanocrystalline core. In an embodiment, the mercaptoalkanoic acid has one mercapto group, one carboxyl group and from one to six carbon atoms. For example, the mercaptoalkanoic acid can be mercaptoacetic acid.

[0048] The biofunctional group can be linked to the nanocrystalline core, or it can be linked to a shell layer which overcoats the nanocrystalline core. Certain saccharides are biofunctional groups. In this application, the term "saccharide" refers to mono-, di-, tri-, and oligosaccharides. The saccharide can be a saccharide found in nature, or can be a saccharide which is not found in nature. A saccharide may be, for example, an antigen found on the membrane of a tumor cell or a bacterium. For example, Thomsen-Friedenreich disaccharide is found on the surface of many human cancer cells but not on the surface of normal human cells. A saccharide found on the surface of cancer cells, but not on the surface of normal human cells can be referred to as a tumor-associated carbohydrate antigen.

[0049] The term "linked" is used herein to mean either directly linked or indirectly linked. In a first example, a first chemical group is directly linked to a second chemical group if there is a link between an atom or a portion of the first chemical group, and a link between an atom or a portion of the second chemical group. In a second example, a first chemical group is indirectly linked to a second chemical group if there is a link between an atom or a portion of the first chemical group and a third chemical group, and another link between the third chemical group and a second chemical group. Referring to a first chemical group as "linked" to a second chemical group means that the link could be direct, as in the

first example, or indirect, as in the second example.

[0050] A chemical group, e.g., a biofunctional group, can be linked to a nanocrystalline core directly, or it can be linked to a nanocrystalline core indirectly, for example, through a linking group. A linking group can play a number of different roles. For example, a linking group may act as a "spacer" between the nanocrystalline core or shell layer and the biofunctional group so that the biofunctional group can assume a conformation required to stimulate or suppress the response of a biological system as desired. A linking group can also act to separate charge in or on the nanocrystalline core or shell layer from the biofunctional group. A linking group can facilitate linking a biofunctional group to a nanocrystalline core or shell layer. For example, a biofunctional group can be linked to a linking group, the linking group can include an atom which has a high affinity for a nanocrystalline core and thus links to the nanocrystalline core or shell layer or integrates with the nanocrystalline core. For example, a biofunctional group can be linked to a sulfur atom, the sulfur atom serving as a linking group, and the sulfur atom can in turn be linked to the surface of a nanocrystalline core. As another example, a saccharide which is a biofunctional group can be linked to a linking group including a chain of at least one carbon atom. The linking group can further include a sulfur atom. The sulfur atom can then be linked to a nanocrystalline core, for example, a cadmium selenide or cadmium telluride nanocrystalline core. A atom which links directly to a nanocrystalline core, for example, a sulfur atom, can be referred to as part of a linking group or as a linking group in itself. Alternatively, an atom which links directly to a nanocrystalline core can be referred to as outside of a linking group. That is, the previous example could also be presented as a biofunctional group

linked to a linking group including a chain of at least one carbon atom, with the linking group linked to the sulfur atom, which is linked to the nanocrystalline core. In an embodiment, a Thomsen-Friedenreich disaccharide is covalently bonded to a linking group including a chain of five carbon atoms, which is in turn linked to a sulfur atom, which is in turn linked to a nanocrystalline core of cadmium telluride or cadmium selenide.

[0051] A chemical group can be linked to a shell which overcoats a nanocrystalline core. In this case, the chemical group is still linked to the nanocrystalline core, albeit through the shell. In this case, the shell is considered a linking group. For example, a structure can be presented as an ethylene glycol unit or a biofunctional group lined to the surface of a nanocrystalline core through a linking group, and the linking group can be presented as not including zinc. Therefore, if there is a shell which overcoats a nanocrystalline core, the shell is considered part of the linking group, and the shell, as well as any other portion of the linking group, cannot include zinc.

[0052] In an embodiment, a quantum dot is functionalized with a biofunctional group and with a mercaptoalkanoic acid. The biofunctional group and the mercaptoalkanoic acid are selected so that the biofunctional group has a molecular weight greater than the molecular weight of the mercaptoalkanoic acid. Alternatively, the biofunctional group and the mercaptoalkanoic acid are selected so that the biofunctional group has a molecular volume greater than the molecular volume of the mercaptoalkanoic acid. Such a selection of the biofunctional group and the mercaptoalkanoic acid can be made to ensure that the mercaptoalkanoic acid groups on the surface of a nanocrystalline core or a shell of a quantum dot do

not shield or screen the biofunctional groups from the environment, for example, from molecules or structures in a biological material, such as in a living animal.

[0053] An embodiment of a method for making a biofunctionalized quantum dot is now described. A biofunctional group-thiol of Formula III, in which R_1 represents a group containing one or more carbon atoms, can be refluxed with a cadmium salt, e.g., cadmium perchlorate, a hydrogen alkali telluride, e.g., hydrogen sodium telluride, and a suitable solvent, e.g., water or N,N-dimethylformamide, to produce a quantum dot in which the biofunctional group-thiol of Formula III is linked to the surface of a nanocrystal of cadmium telluride. A hydrogen alkali selenide, e.g., hydrogen alkali selenide, can be used instead of a hydrogen alkali telluride to produce a quantum dot in which the biofunctional group-thiol is linked to the surface of a nanocrystal of cadmium selenide. In an embodiment, the biofunctional group-thiol of Formula III can be a Thomsen-Friedenreich-thiol. In general, the longer refluxing is conducted, the larger the biofunctionalized quantum dots produced will be. In an embodiment, refluxing is conducted for a duration of from about 24 hours to about 48 hours. For example, refluxing can be conducted for 39 hours.



III

[0054] In another embodiment, the mixture which is refluxed also contains a mercaptoalkanoic acid, e.g., mercaptoacetic acid. A biofunctionalized quantum dot is thereby formed in which the biofunctional group-thiol and a

mercaptoalkanoic acid group are linked to the surface of a nanocrystal of cadmium telluride when a hydrogen alkali telluride is used, as shown in Fig. 1. The biofunctional group-thiol and a mercaptoalkanoic acid group can also be linked to the surface of a nanocrystal of cadmium selenide when a hydrogen alkali selenide is used. In an embodiment, the biofunctional group is Thomsen-Friedenreich disaccharide, the mercaptoalkanoic acid is mercaptoacetic acid, and the Thomsen-Friedenreich-thiol and the mercaptoacetic acid are present in a molar ratio of from about 1:1 to about 5:1 in the mixture. For example, they can be in a molar ratio of about 3.4:1.

[0055] In an embodiment, the biofunctional group-thiol of Formula III can be formed by reacting a glycoside of Formula I with a alkylthio acid in the presence of a catalyst to produce a thioester of Formula II, in which R_2 represents a group containing one or more carbon atoms. The thioester of Formula II can then be debenzylidinated and hydrolyzed to produce the biofunctional group-thiol of Formula III in solution. In an embodiment, the glycoside can be selected to produce a Thomsen-Friedenreich-thiol for the compound of Formula III.



I



II

[0056] In an embodiment, the solution containing biofunctionalized quantum dots illustrated in Fig. 1 can be purified, and the purified solution can be dried to isolate a preparation of biofunctional group-functionalized quantum dots. For example, the solution can be filtered through a membrane with a cutoff in the range of 10 to 100 kilodaltons. The cutoff can be selected so that only the desired quantum dots less than a certain size pass through and larger quantum dots and particles are retained; in this case the permeate passing through the filter is dried to obtain isolated biofunctionalized quantum dots. Alternatively, the cutoff can be selected so that the desired quantum dots of greater than a certain size are retained and smaller quantum dots and particles pass through; in this case the retentate retained by the filter is dried to isolate biofunctionalized quantum dots. The solution containing the quantum dots can also be forced through a filter with a larger cutoff, the permeate then passed through a filter with a smaller cutoff, and the retentate of the filter with the smaller cutoff then dried to isolate biofunctionalized quantum dots. Membranes of various types can be used, for example, an ultrafiltration membrane can be used or a dialysis membrane can be used. As an example, the solution containing the quantum dots can be passed through an ultrafiltration membrane with a cutoff of about 50 kilodaltons and the retentate dried to isolate biofunctionalized quantum dots. The isolated biofunctionalized quantum dots can be redissolved or resuspended in an aqueous solvent, for example, a biocompatible aqueous solvent, for further use. A biocompatible aqueous solvent could be a solvent containing components in addition to water and the quantum dots which improve the performance of the water-dissolved or water-suspended quantum dots when they are applied to a

biomaterial. For example, a biocompatible aqueous solvent may be adjusted to have similar salinity and pH as a tissue into which it is to be injected.

[0057] In an embodiment, a biofunctionalized quantum dot is linked to a cell to form a cell-quantum dot complex. For example, the biofunctional group on the quantum dot may act as a ligand which couples with a receptor on the surface of a cell. The biofunctional group on the quantum dot can be, for example, a saccharide, such as Thomsen-Friedenreich disaccharide. For example, the Thomsen-Friedenreich disaccharide may act as a ligand which couples with a receptor protein, galectin-3, on an endothelial cell. In addition to a biofunctional group, the quantum dot may have other groups on the surface of a nanocrystalline core or a shell, such as a mercaptoalkanoic acid, e.g., mercaptoacetic acid.

[0058] In an embodiment, the biofunctionalized quantum dots are in the form of a formulation. Such a formulation includes a liquid and biofunctionalized quantum dots dissolved or suspended in the liquid so that the solution or suspension does not precipitate or flocculate. The biofunctionalized quantum dots according to the invention, when mixed with water, form a solution which is clear, although it may be colored. Thus it appears that the quantum dots dissolve in water. However, the literature on hydrophilic quantum dots often refers to a suspension of quantum dots, it may be that although when mixed with water, the resultant composition is clear, the term "suspension" is used because of the greater size of quantum dots with respect to low molecular weight molecules.

[0059] In an embodiment, the biofunctionalized quantum dots in a formulation have a mercaptoalkanoic acid, e.g., mercaptoacetic acid, linked to the surfaces of a nanocrystalline core or a shell. The biofunctional group can be a saccharide, for example, Thomsen-Friedenreich disaccharide.

[0060] Biofunctionalized quantum dots can be used in systems for assessing characteristics of a biological material. For example, biofunctionalized quantum dots can be used to diagnose disease states of tissue. Such tissue could be evaluated *in vivo*, i.e., while still in an organism, or *in vitro*, e.g., a biopsy sample could be evaluated. A biological material may either be living, i.e., exhibiting metabolism, or nonliving. A non-exhaustive list of examples of biological materials include isolated cells, a number of cells which do not act cooperatively, cells in a cell culture, cells in or removed from a multicellular organism, e.g., an animal, tissue in or removed from a multicellular organism, e.g., portions of organs such as liver, structures in or removed from an organism, e.g., hair, contents of cells, and material secreted by cells or by an organism, e.g., serum, mucus, proteins, or antibodies.

[0061] Biofunctionalized quantum dots can be used in biological or medical imaging applications. In an embodiment, a biofunctionalized quantum dot is contacted with a biological material. The biofunctionalized quantum dots and biological material are then exposed to light having a wavelength effective to cause the quantum dot to fluoresce, i.e., light with a wavelength shorter than the characteristic wavelength of the quantum dot. The biofunctionalized quantum dots and biological material can then be imaged, e.g., through chemical photography or a video camera. The fluorescing regions of the biological material are regions to which the biofunctional groups on the quantum dots adhere. By noting differences in fluorescence intensity resulting from different number density of quantum dots in different regions of the biological material, differences in characteristics of these regions may be detected. Such differences in characteristics can be used to identify tissue in a diseased or abnormal state, for

example, cancerous tissue or tissue infected by bacteria, parasites, or viruses.

[0062] Scientists from the University of Missouri have shown that cancer-associated carbohydrate T antigen, e.g., Thomsen-Friedenreich disaccharide, plays a leading role in docking breast and prostate cancer cells onto endothelium by specifically interacting with an endothelium-expressed protein, galectin-3. The presence of cancer cells in the body may stimulate expression of galectin-3 in endothelial cells.

[0063] Biofunctionalized quantum dots according to the invention can be injected into an organism, for example, into the tissues, including the circulatory system, of a living animal. For example, the biofunctionalized quantum dots can be dissolved or suspended in a biocompatible aqueous solvent, and the solution or suspension then injected into the body. The Thomsen-Friedenreich-functionalized quantum dots of the invention would adhere to cells which express galectin-3, in particular, endothelial cells which have been stimulated to express large amounts of galectin-3. The body or a biopsy of tissue from the body can then be exposed to light which causes the quantum dots to fluoresce, the body or biopsy sample can then be imaged. By noting which regions of tissue fluoresce most intensely, the state of advancement of a tumor, for example, a metastasizing tumor, can be determined. See Glinksky et al., "The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium", *Cancer Res.*, 61 (12): 4851-4857, June 15, 2001. The fact that the biofunctionalized quantum dots of the present application are water-soluble and biocompatible makes them particularly advantageous for use in evaluating tissue in vivo or in vitro.

[0064] Quantum dots can be functionalized with biological receptors

which couple with antigens on cancer cells, these antigens either not being present in normal cells or being present on cancer cells in much greater concentration than in normal cells. Similarly, quantum dots can be functionalized with antigens which couple with receptors on cancer cells, these receptors either not being present in normal cells or being present on cancer cells in much greater concentration than in normal cells. By contacting the quantum dots with tissue in the body or in an in vitro sample and imaging, regions of tissue in which cancer cells have proliferated can be detected.

[0065] In an embodiment, biofunctionalized quantum dots of the invention are used in a biological or medical analysis system. For example, a quantum dot can be functionalized with an antigen to which a pathogen sought to be detected has affinity, e.g., through a receptor on the pathogen. A biological material or substance secreted from a biological material can be brought into contact with the biofunctionalized quantum dot. Coupling of a pathogen to the quantum dot can be detected, for example, by passing a fluid containing the quantum dots and pathogens over an assay plate on which the antigen is fixed. A pathogen to which a quantum dot is coupled and having affinity to an antigen will then couple to the antigen fixed to the plate. By shining light of a shorter wavelength than the characteristic wavelength of the quantum dot, any quantum dots in a pathogen-quantum dot complex affixed to the plate is made to fluoresce. Such fluorescence is then indicative of the presence of the pathogen.

[0066] Similarly, different types of quantum dots can be produced, each functionalized with a different antigen corresponding to an antigen fixed to a specific region of an assay plate. The quantum dots can then be combined with the sample suspected of containing pathogens. A fluid containing the sample and

the quantum dots is then passed over the assay plate. A pathogen bearing a receptor will couple to a quantum dot having the corresponding antigen and to the region of the assay plate having the corresponding antigen. When the quantum dots are made to fluoresce, the fluorescing regions on the plate can be noted. Because the antigen corresponding to a region of the plate is known, the presence of a number of pathogens bearing receptors specific to antigens can be identified.

[0067] As another example, the quantum dots can be functionalized with several antigens. In an embodiment, a number of types of quantum dots are made, each type having a specific size and being made of a specific material so that each type fluoresces at a different wavelength. Each type can be functionalized with a different antigen or with a different set of antigens. The antigens present on the quantum dots can then be distributed over and fixed to an assay plate. Pathogens binding to antigens on the quantum dots would then couple to antigens on the plate surface. By shining light of a shorter wavelength than the characteristic wavelengths of the quantum dots, the quantum dots are made to fluoresce. By determining the wavelengths of the light emitted from the quantum dot – pathogen complexes coupled to the plate surface, the presence of pathogens bearing receptors specific to antigens can be identified. Such assay plates can be in a microchip format to form a "lab on a chip" used in small analytical devices or even implanted in the body.

[0068] Biofunctionalized quantum dots of the invention can also be used together with an assay plate as follows. An antibody is fixed to an assay plate. A sample which may contain antigens or pathogens bearing antigens is brought into contact with the assay plate. Quantum dots are functionalized with the same antibody and brought into contact with the assay plate. Light of a shorter

wavelength than the characteristic wavelength of the quantum dots is then shown on the assay plate. Fluorescence from the quantum dots indicates the presence of the antigen or the pathogen-bearing antigen. This method can be extended to assay plates on which more than one type of antibody is fixed, each antibody being fixed to a specific region of the assay plate. The method can also be extended to a method in which several types of quantum dots fluorescing at different frequencies are functionalized, each type with a different antibody or set of antibodies, the different antibodies are distributed over and fixed to an assay plate, a sample which may contain antigens or pathogen-bearing antigens is brought into contact with the assay plate, and the antibody-functionalized quantum dots are brought into contact with the assay plate.

[0069] Biofunctionalized quantum dots can be used in therapeutic applications. For example, cancer cells may express antigens which couple with receptors on normal cells. Such coupling can play a role in metastasis of cancer cells or other interactions of cancer cells with the body. In an embodiment, quantum dots are functionalized with the same antigens which the cancer cells express, the quantum dots may bind to receptors on normal cells and thereby block adhesion of cancer cells to the normal cells. For example, as discussed above, cancer-associated carbohydrate T antigen, e.g., Thomsen-Friedenreich disaccharide, plays a leading role in docking breast and prostate cancer cells onto endothelium by specifically interacting with an endothelium-expressed protein, galectin-3. Thomsen-Friedenreich-functionalized quantum dots could be injected into the body to adhere to endothelial cells which express galectin-3, in particular, endothelial cells which have been stimulated to express large amounts of galectin-3, and thereby block adhesion of the cancer cells to the endothelium. Such

therapy could delay or prevent the metastasis of cancer cells. See Glinsky et al., "The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium", *Cancer Res.*, 61 (12): 4851-4857, June 15, 2001.

[0070] It is thought that multiple presentations of antigenic saccharides to receptor proteins, i.e., a high concentration of antigenic saccharides, may dramatically increase the strength of coupling between the particle or cell with the antigenic saccharides and the particle or cell with the receptor proteins; this is known as the cluster glycoside effect. Thus, quantum dots can advantageously be used as vehicles to provide antigenic saccharides to receptors proteins, because the antigenic saccharides are present in high concentrations on the surface of a nanocrystalline core or a shell of the quantum dots.

[0071] The biofunctionalized quantum dots presented in this application can be especially useful in that they can be used simultaneously for therapy and diagnosis. For example, biofunctionalized quantum dots can be injected into the body for therapy, and then induced to fluoresce and imaged to monitor the response of the body, especially of diseased tissue, to the therapy.

[0072] As discussed above, quantum dots functionalized with an antigen can bind with diseased cells, e.g., cancer cells, which express a receptor for the antigen, and quantum dots functionalized with a receptor can bind with diseased cells, e.g., cancer cells, which express an antigen which couples with the receptor. In an embodiment, the quantum dot, in addition to the biofunctional antigen or receptor, has a therapeutic agent linked to it. By injecting such a quantum dot, site-specific drug delivery can be achieved. Such site-specific therapeutic agent delivery is of great interest in cancer therapy, as the therapeutic agents used can be

toxic to normal as well as cancerous cells. The therapeutic agent delivered can be a drug, e.g., a drug to stimulate an immune response, a chemotherapeutic agent, e.g., for killing or weakening a cancer cell, or a radiotherapeutic agent for killing or weakening a cancer cell. Alternatively, the nanocrystalline core or the shell layer of the quantum dot may itself serve as the therapeutic agent. For example, radioisotopes may be used as elements in the formation of the semiconductor nanocrystalline core or of the shell layer. Non-radioactive elements or compounds may be selected for their toxicity to cancer cells and selected so that the semiconductor nanocrystalline core or the shell layer which they form degrades over time, exposing the cancer cells to which the quantum dot is bound to these toxic elements or compounds. Drug-functionalized, radioactive, or chemotoxic quantum dots functionalized with an antigen can also be used to selectively weaken or destroy cells in the body which cancer cells co-opt for their growth or proliferation.


[0073] In an embodiment, biofunctionalized quantum dots are used as a component of an immunogenic composition. Tumor-associated antigens expressed by cancerous cells, for example, antigenic saccharides such as Thomsen-Friedenreich disaccharide, can be used to functionalize quantum dots. Introduction of tumor-associated-antigens alone usually fails to stimulate an immune response because of immune self-tolerance. However, multiple and dense presentation of tumor-associated-antigens on the surface of a nanocrystalline core or a shell of a quantum dot may be recognized by the immune system as distinctly unnatural so that an immune response is stimulated. When injected into the body, these tumor-associated antigen-functionalized quantum dots may stimulate an immune response and thus spur the immune system in

attacking the cancerous cells.


[0074] In an embodiment, biofunctionalized quantum dots are used to coat surfaces of devices which come into contact with biological material. Examples of such devices are implants or extracorporeal devices, e.g., dialysis machines. For example, the biofunctional groups on the quantum dots can be selected so that the biological material, e.g., blood or tissue, recognizes the biofunctionalized quantum dots on the device surface as "self" so that an immune or inflammatory response is not stimulated. The coating of foreign surfaces with biofunctionalized quantum dots could be used in a therapeutic, e.g., for coating implants, and in a research context.

EXAMPLE 1

[0075] A solution of a glycoside of Formula IV (120 mg) in anhydrous 1,4-dioxane (4 ml) was purged with argon for 20 min. To this solution was added triply distilled thiolacetic acid (1.4 ml) followed by 2,2'-azobisisobutyronitrile (30 mg). The reaction was left to stir under an argon atmosphere at 75 °C for 12 hours and quenched with cyclohexene (0.1 ml). The solution was co-evaporated with xylenes under reduced pressure. Flash column chromatography of the residue on silica gel with a solution of ethyl acetate and hexanes in a volume ratio of 3:1 provided a thioester of Formula V (125 mg).



IV




V

[0076] The thioester of Formula V was then debenzylidinated. A first approach for debenzylidination was carried out as follows. The thioester of Formula V (110 mg) was dissolved in a solution of 80% acetic acid in water (3 ml) was stirred at 60 °C for 16 hours. The reaction solution was concentrated at reduced pressure and co-evaporated twice with xylenes. The residue was purified by flash column chromatography on silica gel using a solution of 7% methanol in methylene chloride to provide a debenzylidinated thioester (69 mg).

[0077] In a second, alternative approach for debenzylidination, the thioester of Formula V (600 mg) was dissolved in methanol (14 ml) and treated

with 3 drops of acetyl chloride. After 30 minutes, the reaction was quenched with pyridine (1 ml) and evaporated. The residue was purified by flash column chromatography using a solvent of 5% to 10% methanol on methylene chloride to yield a debenzylidinated thioester (475 mg).


[0078] The debenzylidinated thioester was then hydrolyzed. A first approach for hydrolysis was carried out as follows. A solution of debenzylidinated thioester (30 mg) in methanol (5 ml) was treated with a solution of sodium methoxide in methanol (25% w/v, 25 μ l) and allowed to react for 30 minutes. The solution was then neutralized with strongly acidic Amberlite®-120 ion-exchange resin, filtered, and concentrated. Purification was performed on a Strata® SI-1 silica gel cartridge with an eluting solvent of 20% methanol in methylene chloride to yield the Thomsen-Friedenreich-thiol of Formula VI (20 mg) as a white solid.



VI

[0079] In a second, alternative approach for hydrolysis, the debenzylidinated thioester (300 mg) was dissolved in methanol (5 ml). The solution was treated with a solution of sodium methoxide in methanol (25% (w/v), 30 μ l). Air was bubbled through the solution and the solution was stirred at room

temperature and allowed to react for 24 hours. The solution was then neutralized with strongly acidic Amberlite®-120, and evaporated under reduced pressure at 50 °C to yield the Thomsen-Friedenreich-disulfide of Formula VII (200 mg). The Thomsen-Friedenreich-disulfide of Formula VII was purified by reverse phase flash chromatography with aqueous methanol to yield purified Thomsen-Friedenreich-disulfide of Formula VII (187 mg) as a white powder which was soluble in water and in methanol. The Thomsen-Friedenreich-disulfide of Formula VII (130 mg) was then dissolved in distilled water (1 ml) and degassed with argon for 20 minutes. Dithiothreitol (130 mg) was added and the solution allowed to react for 20 minutes. The excess dithiothreitol was then removed by several extractions with ethyl acetate. The residue was then purified by reverse phase flash chromatography on a C-18 column with an aqueous solution of methanol (10%-40% (v/v)) to yield the Thomsen-Friedenreich-thiol of Formula VI. The Thomsen-Friedenreich-thiol of Formula VI could be stored under argon at -20 °C without significant dimerization for weeks but normally was used immediately since it oxidizes to the Thomsen-Friedenreich-disulfide of Formula VII upon standing at room temperature.



VII

EXAMPLE 2

[0080] Hydrogen telluride gas was generated by reacting aluminum telluride (Al_2Te_3 , 123mg) with aqueous sulfuric acid (0.5M, 10 ml). The hydrogen telluride was then passed with a slow flow of argon through a deaerated solution of sodium hydroxide in water (50mM, 10 ml) to yield a solution of hydrogen sodium telluride (NaHTe , 50 mM).

[0081] The Thomsen-Friedenreich-thiol of Formula VI (28 mg) was then dissolved in an aqueous solution of cadmium perchlorate (16 mM, 700 μl) and was purged with argon for 20 minutes. The freshly prepared hydrogen sodium telluride solution (115 μl) was then quickly added to this mixture. The mixture was then refluxed in the open air. During the refluxing, 50 μl aliquots were collected and analyzed for UV absorption. The absorption spectra during the first 2 hours of the synthesis are shown in Fig. 2, in which curve A represents an aliquot taken at 30 minutes, curve B represents an aliquot taken at 60 minutes, curve C represents an aliquot taken at 90 minutes, and curve D represents an aliquot taken at 120 minutes. Rapid growth of the nanocrystals during these first 2 hours is evident from the shift of the absorption maxima to longer wavelengths (see Gaponik et al., J. Phys. Chem. B, (2002) v.106, p. 7177). After 48 hours of refluxing, faint green luminescence was observed. The solution was cooled to ambient temperature, diluted with water, and purified from the low molecular weight impurities on Centriplus[®] YD-30 (MWCO 30KDa) cartridges. Drying of the purified solution yielded Thomsen-Friedenreich-functionalized cadmium

telluride quantum dots as a pale yellow fluffy substance that was freely soluble in water. Comparison of the ^1H NMR spectra of the Thomsen-Friedenreich-thiol of Formula VI (label A) and the Thomsen-Friedenreich-functionalized cadmium telluride quantum dots (label B) in deuterium oxide solution is shown in Fig. 3. The absence of sharp peaks in the spectrum of the Thomsen-Friedenreich-functionalized cadmium telluride quantum dots in deuterium oxide indicates that no free ligands are present in solution.

[0082] In a modified procedure, the Thomsen-Friedenreich-thiol of Formula VI, the cadmium perchlorate, and the hydrogen sodium telluride solution can be dissolved in N,N-dimethylformamide and the solution can be refluxed.

EXAMPLE 3

[0083] Hydrogen telluride gas was generated by reacting aluminum telluride (Al_2Te_3 , 123mg) with aqueous sulfuric acid (0.5M, 10 ml). The hydrogen telluride was then passed with a slow flow of argon through a deaerated solution of sodium hydroxide in water (50mM, 10 ml) to yield a solution of hydrogen sodium telluride (NaHTe , 50 mM).

[0084] The Thomsen-Friedenreich-thiol of Formula VI (12.3 mg) and mercaptoacetic acid (3 ml) were dissolved in an aqueous solution of cadmium perchlorate (16 mM, 1400 μl) and purged with argon for 20 minutes. The freshly prepared hydrogen sodium telluride solution (230 μl) was then quickly added to this mixture under argon. The mixture was then refluxed in the open air. Aliquots were taken after 15, 21, 27, and 39 hours; the intensity of fluorescence was observed to increase with time. After 39 hours of refluxing, bright yellow

luminescence was observed. The solution was cooled to ambient temperature, diluted with water, and purified from low molecular weight impurities on Centriplus® YD-50 (MWCO 50KDa) cartridges. Drying of the purified solution yielded Thomsen-Friedenreich- mercaptoacetic-acid-functionalized cadmium telluride quantum dots (4 mg) as a yellow fluffy substance that was freely soluble in water and dimethylsulfoxide. The mercaptoacetic acid can function as a luminescence promoter, also known as a fluorescence promoter, luminescence enhancer, or fluorescence enhancer.

[0085] The ^1H NMR spectra of mercaptoacetic acid (label A), the Thomsen-Friedenreich-thiol of Formula VI (label B), and the Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots (label C) in deuterium oxide solution are shown in Fig. 4. The broad peaks in the spectrum of the quantum dots (label C) are a result of increased relaxation rates due to effective molecular weight (>50 KDa) of the nanoparticles and the close packing of the mercaptoacetic acid and the Thomsen-Friedenreich-thiol groups on their surfaces. The downfield shift of the $-\text{CH}_2\text{S}-$ methylene triplet (δ 2.6, spectrum B) may be attributed to the close proximity of C-S to the semiconductor surface which results in strong electronic interaction. Interestingly, this methylene signal completely disappeared when the Thomsen-Friedenreich-thiol of Formula VI was attached to gold nanoparticles. The chemical shifts of the remaining protons confirmed that the bonded Thomsen-Friedenreich groups have the same structure as in the free Thomsen-Friedenreich thiol. Also noteworthy is the fact that, although a three-fold excess of the Thomsen-Friedenreich-thiol over mercaptoacetic acid was used in the synthesis, the NMR shows that approximately 1.5 molecules of mercaptoacetic acid were incorporated into a quantum dot per

molecule of the Thomsen-Friedenreich-thiol incorporated, as calculated by integration of the methylene signal of mercaptoacetic acid (δ 3.1) and the methyl group on the acetamide group (δ 2.1) of the Thomsen-Friedenreich-thiol. This effect of preferential binding affinity of one ligand over another was reported before in the synthesis of hybrid sugar-bearing gold nanoparticles. See Barrientos et al., *Chem. Eur. J.*, v. 9 (2003) p. 1909. The absence of sharp peaks in the spectrum of the Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots in deuterium oxide solution indicates that no free mercaptoacetic acid or free Thomsen-Friedenreich-thiol of Formula VI is present in solution. The absorption spectrum of Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots is shown in Fig. 5 in which the first excitonic maximum at 460 nm is apparent.

[0086] Coupling between Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots and a monoclonal anti-Thomsen-Friedenreich antibody was observed. Imaging with a laser scanning confocal microscope clearly revealed time-dependent aggregation of the quantum dots over time after addition of the antibody. This result confirms that the functional integrity of the Thomsen-Friedenreich antigen is conserved while the antigen is linked to the quantum dot.

[0087] The Thomsen-Friedenreich- mercaptoacetic-acid-functionalized cadmium telluride quantum dot samples showed prolonged stability of their luminescence against oxidation. Thus, solutions of pure Thomsen-Friedenreich-mercaptoacetic-acid-functionalized cadmium telluride quantum dots in water stored in the dark at 4 °C for at least 4 months exhibited no signs of decreased luminescence or precipitation or flocculation. NMR analysis of samples indicated

that there was no leaching of the mercaptoacetic acid or Thomsen-Friedenreich groups from the quantum dot into the water. This stability is remarkable. Similarly prepared mercaptoacetic acid or mercaptopropionic acid capped quantum dots, which were not capped with a saccharide group completely flocculated in a few days when stored in aqueous solution in the absence of free ligand.

[0088] In a modified procedure, the Thomsen-Friedenreich-thiol of Formula VI, the mercaptoacetic acid, the cadmium perchlorate, and the hydrogen sodium telluride solution can be dissolved in N,N-dimethylformamide and the solution refluxed.

[0089] In summary, a simple aqueous synthesis of robust, luminescent tumor-associated-carbohydrate-antigen-encapsulated cadmium telluride quantum dots is reported for the first time.

[0090] Biofunctionalized quantum dots according to the invention can include a nanocrystalline core exhibiting quantum confinement and having a surface. A luminescence promoter can be linked to the surface. The luminescence promoter can be, for example, an ethylene glycol unit or an alkylthio acid, such as mercaptoacetic acid. A biofunctional group can be linked to the surface. A luminescence promoter which includes an ethylene glycol unit can improve the specificity of the binding of the biofunctional group with cells or structures complementary to the biofunctional group, for example, receptors. Ethylene glycol units can improve the solubility of a biofunctionalized quantum dot in water.

[0091] An example of an alkylthio acid is mercaptoacetic acid. Another

example of an alkylthio acid is mercaptopropionic acid.

[0092] In an embodiment, a carboxylic acid unit is linked to the nanocrystalline surface. A carboxylic acid unit may be part of or separate from a biofunctional-group-containing linked chain and may be part of or separate from an ethylene-glycol-containing linked chain. A carboxylic acid unit can be used as a point of attachment of biofunctional units or other chemical groups after formation of the quantum dot.

[0093] A biofunctional group includes at least one biofunctional unit. A biofunctional group can have one or more effects upon a living organism or can be found in a living organism. A set of biofunctional units is considered to be a biofunctional group when removal of one unit would change or eliminate the effect the biofunctional group has on a living organism. For example, Thomsen-Friedenreich disaccharide is comprised of two monosaccharides; with only one of the monosaccharides the effect of the monosaccharide on processes in a living organism can be different than the effect of the Thomsen-Friedenreich disaccharide.

[0094] A biofunctional unit is a chemical compound of a type the members of which have been considered to exhibit similar structural or functional characteristics in the biological, molecular biological, or biochemical literature. In this text, a biofunctional unit does not include ethylene glycol or a thioalkyl, e.g., mercaptoacetic acid. A biofunctional unit of a given type of compound cannot be subdivided further and still exhibit the characteristics of the type of compound. For example, a monosaccharide, a mononucleoside, a mononucleotide unit, and a mono-peptide, i.e., an amino acid can be biofunctional units. A

disaccharide, e.g., Thomsen-Friedenreich disaccharide, is considered a saccharide, and is considered a biofunctional group, rather than a biofunctional unit, because it includes two monosaccharides. Certain biofunctional groups may include only one biofunctional unit. A lipid is also an example of a biofunctional unit; a lipid including a single hydrophilic head and one or more hydrophobic tails is considered a single biofunctional unit. A glycopeptide unit includes one monosaccharide and one monopeptide, because without one of these components, the glycopeptide would be either a monosaccharide or a monopeptide; a biofunctional group exhibiting a biological effect may include more than one glycopeptide units, and may include, for example, monosaccharide or monopeptide units between glycopeptide units. Similarly, a glycolipid unit includes one monosaccharide and one lipid unit.

[0095] Analogously, an ethylene glycol monomer is considered to be an ethylene glycol unit. One, two, or more ethylene glycol monomers linked together are considered an ethylene glycol group. However, the term "chemical group" is used in its ordinary sense: one or more atoms which exhibit a recognized behavior. The term "linked" as used in this text is inclusive of both direct and indirect linking of an agglomeration of atoms, chemical group, or an atom to another agglomeration, chemical group, or atom. For example, a sulfur atom is considered linked to a nanocrystalline core of a quantum dots if the sulfur atom is attached through a covalent or other type of bond. When an ethylene glycol unit is covalently bonded to an alkyl chain, and the alkyl chain is covalently bonded to a sulfur atom attached to a nanocrystalline core, the ethylene glycol unit is also referred to as being bound to the nanocrystalline core.

[0096] All atoms within a linked chain are linked to each other, for

example, covalently bonded to each other. A linked chain lies entirely outside of the nanocrystalline core, i.e., a linked chain does not include the nanocrystalline core itself. A linked chain is directly linked to the surface of a nanocrystalline core; for example, a sulfur atom in the linked chain can directly link to the surface of a nanocrystalline core, with the other atoms in the linked chain being linked to the sulfur atom. If two different atoms are linked to each other directly or through other atoms outside of the nanocrystalline core, and both atoms are directly linked to the nanocrystalline core, the two different atoms are still considered to be part of the same linked chain. If atoms are linked outside of the nanocrystalline core to form a branched structure, and one or more of the atoms are directly linked to the surface of the nanocrystalline core, the branched structure is considered a single branched linked chain.

[0097] When a chemical group is linked to a shell, the shell is considered part of the linking group which links the chemical group to the nanocrystalline core. A chemical group directly linked to a shell is considered to be directly linked to the underlying nanocrystalline core. However, if two chemical groups are not linked to each other outside of the shell, and are each linked to the shell at different sites on the shell, each chemical group is considered to be an independent linked chain. That is, for purposes of counting the number of linked chains, two chemical groups attached at different sites on the shell are not considered to be a single linked chain.

[0098] An ethylene-glycol-containing linked chain includes at least one ethylene glycol unit, may include other atoms, and is directly linked to the surface of the nanocrystalline core. A biofunctional-group-containing linked chain includes at least one biofunctional group, may include other atoms, and is directly

linked to the surface of the nanocrystalline core. A mercaptoalkanoic-acid-containing linked chain includes at least one mercaptoalkanoic acid unit, may include other atoms, and is directly linked to the surface of the nanocrystalline core. A mercaptoalkanoic acid molecule linked to the surface of the nanocrystalline core is a mercaptoalkanoic-acid-containing linked chain; a bifunctional group molecules linked to the surface is a bifunctional-group-containing linked chain.

[0099] A linked chain which includes both an ethylene glycol unit and a bifunctional group is considered to be both an ethylene-glycol-containing linked chain and a bifunctional-group-containing linked chain. If the total number of linked chains directly linked to a nanocrystalline core are counted, such a linked chain having both an ethylene glycol unit and a bifunctional group is counted as a single linked chain. However, if the number of ethylene-glycol-containing linked chains and the number of bifunctional-group-containing linked chains are separately counted, such a linked chain having both an ethylene glycol unit and a bifunctional group is counted once as an ethylene-glycol-containing linked chain and counted again as a bifunctional-group-containing linked chain.

[00100] Quantum dots in a formulation are considered to have precipitated or flocculated if a second phase, e.g., a solid phase, can be observed by the unaided human eye. Quantum dots in a formulation are considered to essentially not have precipitated or flocculated if characteristics of the formulation are otherwise indicative of quantum dots in solution, e.g., coloration or fluorescence, even if there is a small amount of a separate phase visible.

Materials and Methods

[00101] In the course of characterization of quantum dots, formulations, chemical precursors of quantum dots, and other related materials, the following techniques and apparatus were used. Melting points were determined on Fisher-Johns melting point apparatus, the uncorrected results are presented. R_f values refer to TLC performed on Analtech Uniplates GF pre-coated with silica gel 60 to a thickness of 0.25 mm. The spots were visualized by charring with a solution of ammonium molybdate (IV) tetrahydrate (12.5 g) and cerium (IV) sulfate tetrahydrate (5.0 g) in 10% aqueous H_2SO_4 (500 mL). Flash column chromatography was performed under medium pressure using silica gel 60 (230-400 mesh, E. Merck) and usually employed a stepwise solvent polarity gradient, correlated with TLC (thin layer chromatography) mobility.


[00102] NMR spectra were recorded on a Varian InovaUnity-400 instrument with residual $CHCl_3$ (7.26 ppm) or D_2O (4.80 ppm) as the internal standard at frequencies of 399.74 MHz for 1H and 100.51 MHz for ^{13}C . Assignments were based on gCOSY and ^{13}C /DEPT experiments. 1H NMR data are tabulated in the order of multiplicity (s, singlet; d, doublet; dd, doublet of doublets; dt, double of triplets; t, triplet; q, quartet; m, multiplet; brs, broad signal), number of protons, and coupling constant(s) in hertz. IR spectra were taken with a JASCO FT/IR-615 spectrometer. Specific optical rotations were determined using a JASCO-P1010 polarimeter in a 0.5 dm cuvette at 589 nm in chloroform. Five consecutive measurements were taken each time; the average value is given. Positive ion fast-atom bombardment mass spectra (FABMS) were obtained at an accelerating voltage of 6 kV. Glycerol was used as the sample matrix, and ionization was effected by xenon atoms. Elemental analyses were

performed by Atlantic Microlab, Inc., Norcross, GA. Laser scanning confocal microscopy was performed on Zeiss 510 confocal microscope (NCI-Frederick, Confocal Microscopy Facility, Image Analysis Lab).

[00103] Dialysis Slide-A-Lyzer® cassettes (MWCO 10KDa) were from Pierce (www.piercenet.com). Centriplus® centrifugal filter devices (MWCO 10KDa, 30KDa, 50 KDa) were from Millipore (www.millipore.com). TOPO coated core-shell CdSe/ZnS nanocrystals were purchased from Evident Technologies (www.evidenttech.com). The following nanocrystals were used in this work: blue ($d=3.7$ nm, $\lambda_{em}=490$ nm), green ($d=4.3$ nm, $\lambda_{em}=520$ nm), and red ($d=7.3$ nm, $\lambda_{em}=620$ nm). Unless otherwise noted, all other materials were purchased from Aldrich-Sigma (www.aldrich.com) and used without further purification. Al_2Te_3 was purchased from Cerac, Inc. (www.cerac.com).

Synthesis of Thiol of Formula 3


[00104] The following is a synthetic approach for production of the thiol compound of Formula 3 (Arabic numeral 3).



[00105] In a first step, a solution of 120 mg (0.17 mmols) of 1-O-[2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)- α -D-galactopyranosyl]-4-pentene (Figure 1)¹ in 4 ml of

anhydrous 1,4-dioxane was purged with argon for 20 min. To this deoxygenated solution, 1.4 ml (2.55 mmols, 15 equivs) of triply distilled thiolacetic acid was added followed by 30 mg (0.03 mmols) of AIBN (2,2'-azobisisobutyronitrile). The reaction was left to stir under an argon atmosphere at 75 °C until no starting material could be detected by TLC. The reaction was then quenched with cyclohexene (0.1 ml). The solution was co-evaporated with xylenes under reduced pressure. FCC (flash column chromatography) on silica gel with 3:1 EtOAc/hexanes provided 125 mg (99.8%) of white solid (7:3 mixture of amide rotamers). The white solid was identified from the following data as thioacetylpentyl-1-O-2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)- α -D-galactopyranoside (Formula 2). The following data were obtained: R_f 0.19 (3:1 EtOAc/hexanes); $[\alpha]_D = +157.79$ (c 0.22 in CHCl_3); IR (neat) 3099.05, 1752.01, 1689.34, 1368.25, 1220.72; ^1H NMR (400 MHz, CDCl_3) δ = 7.48-7.54 (m, 2H, Ph), 7.27-7.38 (m, 3H, Ph), 5.56 (d, 1H, $J=8.98\text{Hz}$, NH), 5.52 (s, 1H, PhCH), 5.34 (d, 1H, $J=2.34\text{Hz}$, $\text{H}''\text{-4}$), 5.13-5.19 (m, 1H, $\text{H}''\text{-2}$), 4.92-4.98 (m, 2H, $\text{H}''\text{-3}$, $\text{H}'\text{-1}$), 4.76 (d, 1H, $J=7.81\text{Hz}$, $\beta\text{H}''\text{-1}$), 4.62 (m, 1H, $\text{H}'\text{-2}$), 3.90-4.30 (m, 6H, $\text{H}'\text{-6}$, $\text{H}''\text{-6}$, $\text{H}'\text{-4}$, $\text{H}''\text{-5}$), 3.88 (m, 1H, $\text{H}'\text{-3}$), 3.59 (bs, 1H, $\text{H}'\text{-5}$), 3.60-3.70 (m, 1H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 3.35-3.45 (m, 1H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 2.83 (t, 2H, $J=7.42\text{Hz}$, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 2.30 (s, 3H, SAc), 1.93, 1.96, 2.00, 2.01, 2.11 (s, 15H, OAc, NHAc), 1.52-1.62 (m, 4H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 1.34-1.44 (m, 2H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$); ^{13}C NMR (100 MHz, CDCl_3) δ = 196.00, 170.57, 170.48, 170.40, 169.73, 169.68, 137.86, 129.04, 128.34, 126.43, 126.28, 103.27, 101.45, 100.93, 98.31, 98.77, 74.70, 71.37, 70.96, 69.51, 69.07, 68.53, 68.13,


67.14, 63.49, 63.24, 61.49, 48.41, 30.88, 29.57, 29.07, 28.96, 25.62, 25.52, 23.64, 20.89, 20.76; FAB MS m/z : 784.0 (MH^+). Anal: Calcd. For $C_{36}H_{49}NO_{16}$: C 55.16; H 6.30; N 1.79. Found: C 54.89; H 6.32; N 1.87.



[00106] In another synthetic step, a solution of 110 mg (0.14 mmols) of the compound of Formula 2 in 3 ml of 80% AcOH was stirred at 45 °C for 16 hours. The reaction solution was concentrated at reduced pressure and co-evaporated twice with xylenes. The residue was flash chromatographed on silica gel using 7% MeOH in CH_2Cl_2 to provide 69 mg (71% yield) of white foam (7:3 mixture of amide rotamers). Alternatively, 600 mg (0.76 mmols) of Formula 2 was dissolved in 14 ml MeOH and treated with 3 drops of acetyl chloride. Reaction was complete in 30 minutes, quenched with 1 ml pyridine and evaporated. Residue was purified by FCC 5% to 10% MeOH/ CH_2Cl_2 to give 475 mg of the product (90% yield). The product was identified from the following data as thioacetylpentyl-1-O-2-acetamido-2-deoxy-3-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)- α -D-galactopyranoside (Formula 2a). The following data were obtained: MP 95-97 °C; R_f 0.46 (10% MeOH in CH_2Cl_2); $[\alpha]_D^{20} = +107.69$ (c 0.15 in $CHCl_3$); IR (neat); 3552.24, 1750.08, 1688.37, 1656.55, 1545.67, 1370.18, 1220.72; 1H NMR (400 MHz, $CDCl_3$) δ = 5.33 (dd, 1H, $J=0.78, 3.51$ Hz, $H''-4$), 5.11-5.18 (m, 1H, $H''-2$), 4.94 (dd, 1H, $J=3.51, 10.54$ Hz, $H''-3$), 4.78 (d, 1H,

$J=3.51\text{Hz}$, $H'-1$), 4.61 (d, 1H, $J=8.20\text{Hz}$, $\beta H''-1$), 4.51 (td, 1H, $J=3.90$, 10.54Hz , $H'-2$), 3.65-4.18 (m, 8H, $H'-5$, $H'-3$, $H'-6$, $H''-6$, $H'-4$, $H''-5$), 3.60-3.67 (m, 1H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 3.31-3.40 (m, 1H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 2.78-2.85 (m, 2H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 2.70 (bs, 2H, OH), 2.28 (s, 3H, SAc), 1.92, 1.94, 2.00, 2.02, 2.11 (s, 15H, OAc, NHAc), 1.50-1.62 (m, 4H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$), 1.32-1.42 (m, 2H, $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAc}$). ^{13}C NMR (100 MHz, CDCl_3) δ = 196.46, 170.61, 170.39, 170.32, 169.72, 169.55, 101.86, 97.87, 78.38, 71.07, 70.82, 69.69, 69.37, 68.83, 67.89, 67.10, 62.88, 61.52, 48.06, 30.86, 29.57, 29.03, 28.88, 25.61, 23.56, 20.87, 20.81, 20.79, 20.72, 20.67. FAB MS m/z : 696.1 (MH^+). Anal: Calcd. for $\text{C}_{29}\text{H}_{45}\text{NO}_{16}\text{S}$: C 50.06; H 6.52; N 2.01. Found: C 49.55; H 6.53; N 2.00.

Synthesis of T₁-disulfide




[00107] In a synthetic step, a solution of 300 mg (0.43 mmols) of the compound of Formula 2a in 5 ml of MeOH was treated with 30 μl of 25% (w/v) NaOMe/MeOH. The reaction solution was stirred at RT (room temperature) for 24 hours with a flow of air bubbling through the solution to oxidize the SH bond. Initially, two spots were observed by TLC (R_f 0.13 and R_f 0.00 in 20% v/v MeOH/ CH_2Cl_2). The higher R_f spot corresponds to the monomeric thiol of Formula 3 while the lower spot corresponded to the disulfide dimer of Formula

2b. After 24 hours only one spot of the dimer of Formula 2b was observed. The reaction solution was then carefully neutralized with strongly acidic Amberlite®-120; careful neutralization includes monitoring the pH of the solution to ensure that the solution does not become acidic. The neutralized solution was evaporated under reduced pressure at 50 °C to give 200 mg (96% yield) of Formula 2b, pure according to NMR. [Sergei: last phrase is correct, right?]

The crude product was purified by RPFC (reverse phase flash chromatography) on a C-18 column with a ramped methanol concentration of from 10% to 40% (v/v) MeOH/H₂O to give 187 mg (90% yield) of white powder product, identified from the following data as the dimer of Formula 2b. The product was soluble in water and methanol. The following data were obtained for the product: MP 247-249 °C; $[\alpha]_D^{25} = +93.76$ (c 1.6 in MeOH); IR (neat) 3379.64, 2944.77, 2827.13, 2112.64, 1746.23, 1218.79; ¹H NMR (400 MHz, D₂O) δ = 4.91 (d, 1H, J=3.9Hz, α H-1'), 4.50 (d, 1H, J=7.8Hz, β H-1"), 4.34 (m, 1H, H-2'), 4.26 (d, 1H, J=2.7Hz, H-4'), 4.00-4.07 (m, 2H, H-3', H-5"), 3.94 (d, 1H, J=3.5Hz, H-4"), 3.63-3.83 (m, 9H, H-2", H-3", H-5", H-6', H-6", O-CH₂-), 2.81 (t, 2H, CH₂S), 2.06 (s, 3H, NAc), 1.70-1.80 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SH), 1.63-1.70 (2H, OCH₂CH₂CH₂CH₂CH₂SH), 1.48-1.56 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SH); ¹³C NMR (100 MHz, CD₃OD) δ = 172.77 (NHAc), 105.08 (C-1), 97.60, 77.76, 75.52, 73.52, 71.33, 70.85, 69.07, 68.83, 67.54, 61.64, 61.38, 49.19, 38.41, 28.89, 28.81, 24.93, 21.69. FAB MS m/z: 969.2 (MH⁺). Anal: Calcd. for C₃₈H₆₈N₂O₂₂S₂(3xH₂O) C, 44.61; H, 7.29; N, 2.74. Found: C 44.24; H 7.21; N 2.73.


After 30 min, the reaction was carefully neutralized with strongly acidic ion-exchange resin Amberlite®-120, filtered and concentrated. Purification was accomplished on a Strata® SI-1 silicagel cartridge eluting with 20% MeOH in CH_2Cl_2 . This gave 20 mg of a white solid product with a 93% yield, which was identified as a free thiol of Formula 3 with the following data. The free thiol could be stored at -20°C without significant dimerization for weeks but normally was used immediately. The following data were obtained for the product: MP 235-237 $^\circ\text{C}$; R_f 0.13 (20% MeOH in CH_2Cl_2); $[\alpha]_D = +77.95$ (c 0.55 in MeOH); IR (neat); 3303 (brs), 1619, 1553; ^1H NMR (400 MHz, D_2O) δ = 4.92 (d, 1H, $J=3.9\text{Hz}$, $\alpha\text{H-1}''$), 4.50 (d, 1H, $J=7.4\text{Hz}$, $\beta\text{H-1}''$), 4.35 (dd, 1H, $J=3.9, 10.9\text{Hz}$, H-2'), 4.27 (d, 1H, $J=2.7\text{Hz}$, H-4'), 4.00-4.10 (m, 2H, H-3', H-5''), 3.94 (d, 1H, $J=3.1\text{Hz}$, H-4''), 3.50-3.80 (m, 9H, H-2'', H-3'', H-5'', H-6', H-6'', O- CH_2 -), 2.60 (t, 2H, CH_2S), 2.06 (s, 3H, NAc), 1.60-1.70 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.46-1.56 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), ^{13}C NMR (100 MHz, CD_3OD) δ = 172.79 (NHAc), 105.08 (C-1), 97.62, 97.54, 77.69, 75.50, 73.52, 71.33, 70.83, 69.04, 68.85, 67.56, 61.38, 49.19, 33.69, 28.75, 24.81, 21.62, 21.59. FAB MS m/z : 486.0 (MH^+). Anal: Calcd. for $\text{C}_{19}\text{H}_{35}\text{NO}_{11}\text{S}$: C, 47.00; H, 7.27; N, 2.88. Found: C 44.24; H 7.21; N 2.73.



126E-170

[00110] In the following synthetic step, the synthetic approach described in Whitesides, G. et al JACS 113 (1991) 12-20 was applied. A solution of 533 μl of


50% NaOH (6.7 mmols) was added to 10g (35.5 mmols) of hexa(polyethyleneglycol) (Aldrich) at 100 °C and allowed to react for 30 min while stirring. 5-Bromo-1-pentene (1g, 6.7 mmols) was then quickly added and the reaction was stirred at 100 °C for 24 hours. The reaction was diluted with water and extracted six times with EtOAc. The combined organic extracts were evaporated and separated by FCC with 10:1 CH₂Cl₂:MeOH. This gave 1 g of a clear liquid product, which was identified by the following data as the compound of formula 126E-170. The following data on the clear liquid product were obtained: R_f (10:1 CH₂Cl₂:MeOH) = 0.3; IR (neat); 3465 (brs), 2231, 2022, 1690; ¹H NMR (400 MHz, CD₃Cl) δ = 5.73-5.83 (m, 1H, CH=CH₂), 4.90-5.02 (m, 2H, CH=CH₂), 3.53-3.70 (m, 24H, PEG), 3.43 (t, 2H, J = 6.49Hz, OCH₂CH₂CH₂CH=CH₂), 2.08 (m, 2H, OCH₂CH₂CH₂CH=CH₂), 1.65 (m, 2H, OCH₂CH₂CH₂CH=CH₂); ¹³C NMR (100 MHz, CD₃Cl) δ = 72.49, 70.66, 70.59, 70.55, 70.52, 70.33, 70.07, 61.68, 30.19, 28.75. FAB MS m/z: 351.3 (MH⁺), 373.3 (M+Na⁺). Anal: Calcd. for C₁₇H₃₄O₇: C, 58.26; H, 9.78; O, 31.96. Found: C 57.96; H 9.72.



126E-179

[00111] In the following synthetic step, the synthetic approach described in Whitesides, G. et al JACS 113 (1991) 12-20 was applied. A solution of 2.8 g (8 mmols) of the compound of Formula 126E-170 in 30 ml MeOH was treated with

30 mmols (2.3g, 2.3 ml) of freshly distilled HSAC. The solution was purged with argon for 20 minutes and 10 mg of AIBN was added. While reacting overnight, the solution was irradiated with 360 nm light, and was then quenched with 1 ml of cyclohexene and evaporated. The residue was purified by FCC with 15:1 CH_2Cl_2 :MeOH to afford 3g (88%) of a clear liquid product. From the following data, the product was identified as the sulfur-acetylated product of Formula 126E-179. IR (neat); 3465 (brs), 1689; ^1H NMR (400 MHz, CD_3Cl) δ = 3.52-3.72 (m, 24H, PEG), 3.42 (t, 2H, J = 6.49Hz, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 2.84 (d, 2H, J = 6.95Hz, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 2.60 (brs, 1H, OH), 2.29 (s, 3H, SAC), 1.56 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 1.39 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$); ^{13}C NMR (100 MHz, CD_3Cl) δ = 195.91, 72.47, 71.09, 70.61, 70.57, 70.55, 70.36, 70.09, 61.72, 30.62, 29.34, 29.10, 29.01, 25.36; FAB MS m/z : 427.4 (MH^+). Anal: Calcd. for $\text{C}_{19}\text{H}_{38}\text{O}_8\text{S}$: C, 53.50; H, 8.98; O, 30.01. Found: C 52.17; H 8.91.




126F-018


[00112] In the following synthetic step, the synthetic approach described in Whitesides, G. et al JACS 113 (1991) 12-20 was applied. A solution of 1g (2.34 mmols) of the compound of Formula 126E-179 in 15 ml of dry MeOH was treated with 10 drops of 25% w/v NaOMe/MeOH and allowed to react for 30 minutes. The reaction was quenched with Amberlite®-120 ion-exchange resin, filtered and concentrated. The residue was purified by FCC with 15:1 CH_2Cl_2 :MeOH to afford 350mg (40%) of disulfide product which was cleaved to free thiol with DTT as

31978-201280

follows. The solution of 350 mg of the disulfide was treated with excess 10x DTT in water for 1 hour, and was concentrated and purified by FCC with 10% $\text{CH}_2\text{Cl}_2:\text{MeOH}$ to give 340 mg (98%) of a slightly yellow liquid product. The following data obtained on the product were used to identify the product as having Formula 126F-018: ^1H NMR (400 MHz, CD_3Cl) δ = 3.48-3.68 (m, 24H, PEG), 3.38 (t, 2H, J = 6.49Hz, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$); 2.80 (t, 1H, J = 6.03Hz, OH), 2.46 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.54 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.38 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.28 (m, 1H, SH); ^{13}C NMR (100 MHz, CD_3Cl) δ = 72.49, 71.08, 70.51, 70.48, 70.29, 70.05, 61.61, 33.75, 29.01, 24.87, 24.46. FAB MS m/z : 385.3 (MH^+), 407.3 ($\text{M}+\text{Na}^+$). Anal: Calcd. for $\text{C}_{17}\text{H}_{36}\text{O}_7\text{S}$: C, 53.10; H, 9.44; O, 29.13; S, 8.34 Found: C 52.53; H 9.41.



126C-219




126E-181-HI

[00113] A solution of 2.5g (3.26 mmols) of the compound of Formula 126C-219 and 1 g (2.36 mmols) of the compound of formula 126E-179 in CH_2Cl_2 was evaporated and co-evaporated with toluene and the residue was dried under vacuum overnight. The dried mixture was dissolved in 3:1 mixture of anhydrous CH_2Cl_2 :THF (60:20ml) and added via canula to 2 g of flame-dried MS (molecular sieves). After stirring for 20 minutes, 15 μl of trimethyl silyl triflate was quickly injected via syringe, with care taken that the syringe tip was submerged into the solution. After 30 min, the reaction was quenched with Et_3N , filtered and evaporated. The residue was purified by FCC with EtOAc \rightarrow 20:1 CH_2Cl_2 :MeOH to afford a product with a total yield of 79%. 1.5 g of the α -anomer and 400 mg of the β -anomer (α : β =3.75) were obtained.

[00114] Other reaction conditions were tested to identify conditions which led to high α/β stereoselectivity. Lowering temperature lead to lower α/β selectivity. Increasing polarity resulted in better α/β selectivity. A 3:1 mixture of CH_2Cl_2 :THF at ambient temperature gave the highest stereoselectivity.

[00115] The desired α -anomer was isolated as a glassy solid; the α -anomer was identified as having Formula 126E-181-HI from the following data: R_f (10:1 CH_2Cl_2 :MeOH)= 0.8; 4:1 ratio of rotamers. The NMR of the major rotamer is given. ^1H NMR (400 MHz, CD_3Cl) δ = 7.39-7.43 (m, 2H, Ph), 7.20-7.28 (m, 3H, Ph), 5.43 (s, 1H, PhCH), 5.28 (m, 1H, H $^{\alpha}$ -4), 5.17 (dd, 1H, J = 7.88, 10.20Hz, H $^{\alpha}$ -2), 4.98 (d, 1H, J = 3.71Hz, H $^{\alpha}$ -1), 4.92 (m, 1H, H $^{\alpha}$ -3), 4.67 (d, 1H, J = 7.88Hz, H $^{\alpha}$ -1), 4.26 (m, 1H, H $^{\alpha}$ -4), 3.8-4.15 (m, 8H, H $^{\alpha}$ -2, H $^{\alpha}$ -3, H $^{\alpha}$ -6, H $^{\alpha}$ -5, H $^{\alpha}$ -5), 3.52 (m, 24H, PEG), 3.32 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 2.74 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 2.19 (s, 3H, SAC), 2.04, 1.94, 1.92, 1.86 (s, 4x3H,


Ac), 1.46 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 1.30 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$); ^{13}C NMR (100 MHz, CD_3Cl) δ = 195.86, 170.28, 170.23, 170.11, 169.38, 137.73, 128.81, 128.22, 128.08, 126.50, 126.13, 102.41, 100.58, 98.87, 75.81, 71.06, 70.77, 70.55, 70.50, 70.22, 70.07, 69.19, 68.67, 67.51, 66.97, 63.02, 62.39, 61.37, 58.84, 30.61, 29.64, 29.34, 29.09, 28.99, 25.35, 20.69, 20.67, 20.54; FAB MS m/z : 1031.9 (MH^+), 1069.9 ($\text{M}+\text{K}^+$). Anal: Calcd. for $\text{C}_{46}\text{H}_{69}\text{N}_3\text{O}_{21}\text{S}$: C, 53.53; H, 6.74; N, 4.07; O, 32.55; S, 3.11 Found: C 52.17; H 6.71. The side-product was isolated as a glassy solid and found to have R_f (10:1 CH_2Cl_2 :MeOH) = 0.5.



126E-188-HI

[00116] A solution of 1.5g of the compound of Formula 126E-181-HI in 30ml THF, 15ml AcOH and .5ml acetic anhydride was treated with 15 g of Zn dust. After 4 hours of reaction, the solution was filtered through a pad of Celite®; the Zn cake was washed with EtOAc. The filtrate was washed successively with water, saturated NaHCO_3 and brine. The organic layer was dried over MgSO_4 , evaporated and flash-chromatographed with 20:1 CH_2Cl_2 :MeOH to afford 1.2g (79% yield) of a glassy solid product. The following data were used to identify the product as of Formula 126E-188-HI: R_f (20:1 CH_2Cl_2 :MeOH) = 0.2; $[\alpha]_D = +72.38$ (c 1.37 in CHCl_3); ^1H NMR (400 MHz, CD_3Cl) δ = 7.52-7.57 (m, 2H,


Ph), 7.30-7.40 (m, 3H, Ph), 5.96 (d, 1H, $J = 9.27\text{Hz}$, NH), 5.56 (s, 1H, PhCH), 5.38 (m, 1H, $H''-4$), 5.20 (dd, 1H, $J = 7.88, 10.66\text{Hz}$, $H''-2$), 4.99 (m, 2H, $H'-1$, $H''-3$), 4.77 (d, 1H, $J = 7.88\text{Hz}$, $H''-1$), 4.67 (m, 1H, $H'-2$), 3.72-4.30 (m, 8H, $H'-2$, $H'-3$, $H'-6$, $H''-6$, $H'-5$, $H''-5$), 3.65 (m, 24H, PEG), 3.44 (t, 2H, $J = 6.49\text{Hz}$, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 2.86 (t, 2H, $J = 7.42\text{Hz}$, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 2.32 (s, 3H, NHAc), 2.15 (s, 3H, SAC), 2.05, 2.04, 1.98, 1.97 (s, 4x3H, Ac), 1.59 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$), 1.42 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SAC}$); ^{13}C NMR (100 MHz, CD_3Cl) $\delta = 170.27, 170.12, 169.53, 169.36, 137.74, 128.71, 128.10, 128.06, 126.62, 126.21, 126.06, 101.40, 100.59, 98.57, 75.70, 74.52, 71.05, 70.85, 70.74, 70.54, 70.52, 70.36, 70.06, 69.99, 69.27, 68.81, 67.23, 66.96, 63.13, 61.25, 18.12, 30.60, 29.32, 29.08, 28.98, 25.33, 23.39, 20.68, 20.53$. FAB MS m/z : 1048.2 (MH^+). Anal: Calcd. for $\text{C}_{48}\text{H}_{73}\text{NO}_{22}\text{S}$: C, 55.00; H, 7.02; N, 1.34; O, 33.58; S, 3.06. Found: C 54.57; H 7.06; N 1.43



126E-190-HI

[00117] A solution of 1.2g (1.14 mmols) of the compound of formula 126E-188-HI in 20 ml of dry MeOH was treated with a few drops of AcCl for 1.5 hours, quenched with pyridine, evaporated and purified by FCC with 20:1 \rightarrow 10:1 CH_2Cl_2 :MeOH to afford 700mg (65%) of a glassy solid product. The following data were used to identify the product as of Formula 126E-190-HI: R_f (10:1 CH_2Cl_2 :MeOH) = ; $[\alpha]_D = +47.57$ (c 0.60 in MeOH); ^1H NMR (400 MHz, CD_3Cl)


δ = 5.90 (d, 1H, J = 9.74Hz, NH), 5.37 (m, 1H, Hⁿ-4), 5.20 (dd, 1H, J = 7.88, 10.66Hz, Hⁿ-2), 5.00 (m, 1H, Hⁿ-3), 4.86 (d, 1H, J = 3.71Hz, Hⁱ-1), 4.66 (d, J = 8.34Hz, Hⁿ-1), 4.57 (m, 1H, Hⁱ-2), 3.76-4.22 (m, 7H, Hⁱ-3, Hⁱ-6, Hⁿ-6, Hⁱ-5, Hⁿ-5), 3.54-3.72 (m, 24H, PEG), 3.45 (t, 2H, J = 6.49Hz, OCH₂CH₂CH₂CH₂CH₂SAc), 2.86 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SAc), 2.32 (s, 3H, NHAc), 2.16 (s, 3H, SAc), 2.08, 2.06, 1.99, 1.98 (s, 4x3Ac), 1.59 (m, 4H, OCH₂CH₂CH₂CH₂CH₂SAc), 1.42 (m, 2H, OCH₂CH₂CH₂CH₂SAc); ¹³C NMR (100 MHz, CD₃Cl) δ = 195.90, 170.36, 170.17, 170.06, 169.59, 169.35, 101.63, 98.15, 78.10, 71.04, 70.77, 70.64, 70.56, 70.53, 70.48, 70.44, 70.20, 70.04, 69.97, 69.81, 69.10, 68.58, 67.05, 66.94, 62.51, 61.28, 47.81, 30.59, 29.31, 29.05, 28.96, 25.32, 23.30, 20.64, 20.60, 20.57, 20.50. FAB MS m/z : 961.4 (MH⁺). Anal: Calcd. for C₄₁H₆₉NO₂₂S: C, 51.29; H, 7.24; N, 1.46; Found: C 50.47; H 6.91; N 1.55.



126F-004

[00118] A solution of 500mg of a compound of Formula 126E-190-HI (0.52 mmols) in 20ml of dry MeOH was treated with 7 drops of 25% w/v NaOMe/MeOH and stirred at room temperature for an hour. The reaction was quenched with Amberlite®-120 ion-exchange resin, filtered and evaporated. The residue was cleanly purified with 20% MeOH in CH₂Cl₂ to give 350mg (90%) of glassy solid product after lyophilization. [90% yield?] The product was identified


as of Formula 126F-004 with the following data: R_f (20% MeOH in CH_2Cl_2) = 0.20; $[\alpha]_D = +24.36$ (c 0.24 in MeOH); ^1H NMR (400 MHz, D_2O) δ = 4.80 (d, 1H, J = 3.71Hz, $\text{H}'\text{-1}$), 4.35 (d, 1H, J = 7.88Hz, $\text{H}''\text{-1}$), 4.24 (dd, 1H, J = 3.71, 10.66Hz, $\text{H}'\text{-2}$), 4.12 (m, 1H, $\text{H}''\text{-4}$), 3.94 (dd, 1H, J = 2.78, 11.13Hz, $\text{H}''\text{-3}$), 3.48-3.90 (m, 33H, 24H PEG, NH, $\text{H}'\text{-3}$, $\text{H}'\text{-4}$, $\text{H}'\text{-5}$, $\text{H}''\text{-5}$, $\text{H}'\text{-6}$, $\text{H}''\text{-6}$), 3.43 (m, 3H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$, $\text{H}''\text{-2}$); 2.44 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.91 (s, 3H, NHAc), 1.50 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.33 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$); ^{13}C NMR (100 MHz, D_2O) δ = 174.44, 101.75, 97.42, 97.30, 77.25, 74.92, 72.51, 70.87, 70.71, 70.57, 69.57, 69.11, 68.78, 68.69, 68.59, 68.48, 66.40, 61.16, 60.91, 48.45, 32.75, 27.98, 24.02, 23.66, 22.06, 22.04; FAB MS m/z : 750.3 (MH^+), 788.3 ($\text{M}+\text{K}^+$).



126F-062

[00119] The thiol of Formula 126F-004 dimerized on storage into a disulfide, which has identified as of Formula 126F-062 with the following data. The dimer of Formula 126F-062 was separated from thiol by FCC with a ramped methanol concentration of from 20% to 30% MeOH in CH_2Cl_2 . R_f = 0.15 (30% MeOH in CH_2Cl_2); ^1H NMR (400 MHz, D_2O) δ = 4.80 (d, J = 3.81Hz, $\text{H}'\text{-1}$), 4.34 (d, J = 7.61Hz, $\text{H}''\text{-1}$), 4.24 (m, 1H, $\text{H}'\text{-2}$), 4.12 (m, 1H, $\text{H}''\text{-4}$), 3.94 (dd, 1H, J = 2.93, 11.12Hz, $\text{H}''\text{-3}$), 3.48-3.90 (m, 33H, 24H PEG, NH, $\text{H}'\text{-3}$, $\text{H}'\text{-4}$, $\text{H}'\text{-5}$, $\text{H}''\text{-5}$,

H'-6, H''-6), 3.43 (m, 3H, OCH₂CH₂CH₂CH₂CH₂SH, H''-2); 2.66 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SH), 1.91 (s, 3H, NHAc), 1.62 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SH), 1.51 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SH), 1.34 (m, 2H, OCH₂CH₂CH₂CH₂CH₂SH); ¹³C NMR (100 MHz, D₂O) δ= 174.41, 104.71, 97.43, 97.31, 77.33, 77.27, 74.90, 72.51, 70.81, 70.69, 70.56, 69.61, 69.22, 68.78, 68.67, 68.58, 68.48, 66.39, 61.14, 60.89, 48.44, 38.19, 28.23, 24.23, 22.06, 22.04. Anal: Calcd. for C₆₂H₁₁₆N₂O₃₄S₂: C, 49.72; H, 7.81; N, 1.87; Found: C 50.12; H 7.72.




126F-005

[00120] A glassy solid product was isolated from the deacetylation reaction. The product resulted from incomplete debenzylidenation in a previous step combined with the closeness of R_f values of 126E-188-HI and 126E-190-HI which precluded complete separation. The following data lead to identification of the product as of Formula 126F-005: R_f (20% MeOH in CH₂Cl₂) = 0.45; [α]_D = +89.60 (c 0.33 in MeOH); ¹H NMR (400 MHz, CD₃Cl) δ= 7.50-7.54 (m, 2H, Ph), 7.28-7.36 (m, 3H, Ph), 6.42 (d, 1H, J= 8.81Hz, NH), 5.54 (s, 1H, PhCH), 4.99 (d, 1H, J= 3.25Hz, H'-1), 4.64 (m, 1H, H'-2), 3.60-4.35 (m, 37H, 24H PEG, H''-1, H''-2, H'-3, H'-4, H''-4, H'-5, H''-5, H'-6, H''-6, OCH₂CH₂CH₂CH₂CH₂SH), 2.36 (brs, 1H, OH), 2.52 (dd, 2H, J= 7.42, 14.37, OCH₂CH₂CH₂CH₂CH₂SH), 1.98 (s,

3H, NHAc), 1.61 (m, 4H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.44 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{SH}$), 1.34 (t, 1H, $J = 7.88\text{Hz}$, SH). ^{13}C NMR (100 MHz, CD_3Cl) $\delta = 171.97, 137.95, 128.97, 128.14, 126.77, 105.56, 101.06, 98.64, 75.95, 74.34, 73.27, 71.15, 70.55, 70.51, 70.40, 70.08, 69.97, 69.21, 68.84, 67.27, 63.28, 61.71, 48.57, 33.80, 29.04, 24.91, 24.54, 23.51$; FAB MS m/z : 838.3 (MH^+), 860.3 ($\text{M}+\text{Na}^+$).

[00121] The compound of Formula 126F-005 was further debenzilydenated to produce additional compound of Formula 126F-004, using the synthesis step for making the compound of Formula 126E-190-HI.


Preparation of T_Γ -Encapsulated CdSe/ZnS Nanocrystals via TOPO Ligand Displacement



Method A²: Phase-Transfer from Organic to Aqueous Phase


[00122] A solution of the thiol of Formula 3 (20 mg, 0.041 mmols) in 2 ml of deionized UltraPure[®] water was adjusted to pH 10 with concentrated TMAH (teramethylammonium hydroxide) pentahydrate in water. This solution was added to 1 ml of TOPO-coated CdSe/ZnS in toluene (0.5 mg/ml) and the reaction vessel

was sealed under argon. The reaction temperature was adjusted to 60 °C for 2 hours and then the reaction was left overnight at ambient temperature with vigorous stirring. The organic phase became colorless with no luminescence while the aqueous layer had the color and luminescence of the nanocrystals. The aqueous phase was isolated, washed a few times with Et₂O (diethyl ether), diluted with water, concentrated by ultrafiltration on Millipore's Centriplus® YM-30 (MWCO 30KDa) to 100µl and freeze-dried. Dry quantum dots were freely soluble in water but flocculated after only a few days in solution. Phase transfer from diethyl ether and chloroform, instead of from toluene, produced similar results. The NMR spectrum of quantum dots prepared in the manner outlined in this paragraph shows incomplete (ca. 1:1) displacement of TOPO (Figure 11). Noteworthy are the two signals appearing around 0 ppm. These signals presumably correspond to the CH₂-S- methylenes of the sugar (0 ppm) and methylenes of the octyl chain (-0.1 ppm) of TOPO [(CH₂)₈P=O] next to the quantum dot surface. The signal at -0.1 ppm disappeared when TOPO was completely displaced by the sugar (Figure 12, below). This upfield signal was also observed in chloroform solution of the commercial TOPO-CdSe/ZnS quantum dots.

MR in D₂O of T₇-TOPO-CdSe/ZnS QDs prepared by the seed-mediated growth method.

B^{3,4}: Direct TOPO Displacement in Methanolic Sus

A solution of 20 mg (0.041 mmols) of the thiol of F was basified to pH 10 by dropwise addition of concentrated NaOH. The solution was then transferred to the stirred suspension of CdSe/ZnS in 1 ml of MeOH via syringe under argon. The mixture was purged with argon for 20 min and the vessel was sealed. The reaction was stirred for 24 hours at 50 °C. The suspension was centrifuged at 10,000 rpm for 10 min to remove the precipitate. TLC of the supernatant showed that the reaction was complete when the reaction was stopped. The precipitate was washed with 5x5ml, centrifuged and decanted. Vacuum-dried QDs were obtained. The IR of the quantum dots in D₂O showed complete disappearance of the peak at 1715 cm⁻¹ corresponding to the carbonyl group of TMAH being a major impurity (Figure 12).



[00124] A solution of 50mM NaHTe was prepared by passing H_2Te gas generated by reaction of 123mg (0.28 mmols, 0.85mmols in Te) of Al_2Te_3 with 10 ml of 0.5M H_2SO_4 with a slow flow of argon through deaerated 10 ml of 50mM NaOH solution. The resulting NaHTe solution was light purple and clear. A solution of 28 mg (0.058 mmols) of the thiol of Formula 3 in 700 μ l (0.011 mmols) of 16mM $Cd(ClO_4)_2 \cdot H_2O$ was adjusted to pH 10 with 1M NaOH and purged with argon for 20 min. prior to quick injection of 115 μ l (0.0057 mmols) of the freshly prepared solution of NaHTe. The reaction solution immediately turned light-orange. The ratios of reactants were as follows: $Cd^{2+} : Te^{2-} : \text{thiol of Formula 3} = 1 : 0.5 : 5.2$.⁵ The reaction was set to reflux under open air. In a few minutes the solution became yellow. During the reflux, 50 μ l aliquots were collected and analyzed for UV absorption. The absorption spectra during the first 2 hours of the synthesis are shown in Figure 13. Rapid growth during this time is evident from the shift of the absorption maxima to longer wavelengths.⁵ After 48 hours only faint green luminescence was observed. The solution was cooled to room temperature, diluted with water and purified from low MW impurities on Centriplus® YD-30 (MWCO 30KDa) centrifugal device. Lyophilization of the purified solution gave 5 mg of Tr-CdTe QDs (Thomsen-Friedenreich-

functionalized cadmium-telluride quantum dots) as a pale yellow fluffy substance which was freely soluble in water. NMR of the Tf-CdTe QD solution in D₂O is shown in Figure 14. Absence of sharp peaks in the spectrum indicates that no free ligands are present in solution.




Figure 13. The changes in the absorption spectra of growing Tf-CdTe QDs.

(A) 30 min; (B) 60 min; (C) 90 min; (D) 120 min.




Figure 14. NMR spectra in D_2O of (A) thiol of Formula 3; (B) T-CdTe QDs.

Preparation of Hybrid T-MAA-CdTe QDs via Self-Assembly in Aqueous Solution⁵




Figure 14tt

[00125] A solution was made of 12.3 mg (0.025 mmols) of the thiol of Formula 3 and 6 μ l (8 mg, 0.085 mmols) of mercaptoacetic acid (MAA) in 1400 μ l (0.022 mmols) of 16mM solution of $Cd(ClO_4)_2 \cdot H_2O$. The pH of the solution

was adjusted to 10 with 1M NaOH and the solution was purged with argon for 20 min. prior to brisk addition of 230 μ l (0.011 mmols) of freshly prepared 50mM NaH₂Te solution under argon. The reaction solution immediately became light-orange. The ratios of reactants were as follows: Cd²⁺ : Te²⁻ : R-SH [thiol of Formula 3 : MAA] = 1 : 0.5 : 5 [1 : 3.4]. R-SH indicates a mercapto group linked to another chemical group. The reaction was set to reflux under open air. In a few minutes solution became yellow. 50 μ l aliquots were collected after 15h, 21h, 27h and 39h of reflux and analyzed for UV absorption and luminescence. After 39 hours of reflux bright yellow luminescence was observed. The solution was cooled to the room temperature, diluted with water and purified from low MW impurities on a Centriplus® YD-50 (MWCO 50KDa) centrifugation device. Lyophilization of the purified solution gave 4 mg of product, which was an orange fluffy substance, freely soluble in water. The NMR spectrum of the product solution in D₂O is shown in Figure 15. Absence of sharp peaks in the spectrum indicated that no free ligands were present in solution. The product was understood to be T₇-MAA-CdTe hybrid QDs (Thomsen-Friedenreich- and mercaptoacetic acid-functionalized cadmium-telluride hybrid quantum dots), shown in Figure 14tt.




Figure 15. NMR spectra in D₂O of (A) mercaptoacetic acid (MAA); (B) thiol of Formula 3; (C) T₇-MAA-CdTe QDs.

Preparation of mTEG-CdTe QDs via Self-Assembly in Aqueous Solution⁵




Figure 15aa

[00126] A solution of 120 mg (0.667 mmols) of mTEGSH (mercapto

triethylene glycol) (Davidson, F. + JACS 2003, 125, 7790-1) in 21 ml of 16 μ M Cd(ClO₄)₂ was purged with argon for 10 minutes (no pH adjustment was made), then 3.5 ml of 50mM freshly-prepared solution of NaHTe was added. The solution immediately became yellow-orange. When heating to reflux was commenced, a greenish-yellow precipitate formed on the flask wall. Cooling of the solution back to room temperature resulted in complete dissolution of the precipitate. The reaction solution was refluxed overnight. The ratio of reactants was as follows: TEGSH : Cd²⁺ : Te²⁻ = 3.8 : 2 : 1. In 16 hours the color of the precipitate changed from green to orange while the reaction solution remained clear and nearly colorless. The pH of the solution was 3.6. When the reaction was cooled to room temperature, the orange precipitate completely dissolved; the resulting orange solution had bright green luminescence under UV light. The ethylene glycol unit can function as a luminescence promoter, also known as a fluorescence promoter, luminescence enhancer, or fluorescence enhancer. The solution of TEGS-CdTe QDs (mercapto triethylene glycol functionalized quantum dots) was purified with a 50KDa MWCO filter, lyophilized, redissolved in D₂O and analyzed by NMR (Figure 15b). Remarkably, the solution of the thus prepared TEGS-CdTe QDs readily formed an orange precipitate on heating to 60-70 °C but redissolved readily upon cooling to room temperature. The heating-cooling cycle could be repeated indefinitely without deteriorating the particles.

[00127] It is hypothesized that the behavior of precipitation upon heating and redissolution upon cooling is associated with the conformation of the TEGS (triethylene glycol-sulfur) groups linked to the surface of the cadmium telluride nanocrystal. At low temperatures, the TEGS groups may adopt a conformation such that they coil up close to or lie down on the surface of the cadmium telluride

nanocrystal (see Figure 15aa). The surrounding polar solvent, e.g., water, would then "see" the hydrogen-bonding oxygen atoms of the backbone of the TEGS group surrounding the cadmium telluride nanocrystal, so that dissolution would be thermodynamically favorable. At high temperatures, the TEGS groups may adopt an expanded conformation. The cadmium telluride surface, which does not form hydrogen bonds, would then be exposed to the surrounding polar solvent, e.g., water (see Figure 15aa). The cadmium telluride may not interact or only interact weakly with the polar solvent, so that formation of a separate TEGS-CdTe phase would be thermodynamically favorable, resulting in precipitation. The behavior of precipitation at higher temperatures and dissolution at lower temperatures suggest that the TEGS-CdTe QDs may find application as sensors or in thermal protection devices.




Figure 15b NMR spectra in D₂O of (top) mTEG-SH; and (bottom) mTEG CdTe QDs.

Preparation of Hybrid T_F-mTEG-CdTe QDs via Self-Assembly in Aqueous

Solution⁵




Figure 15bb

[00128] A solution of 26 mg (0.054 mmols) of TfSH $-(\text{CH}_2)_5\text{SH}$ functionalized Thomsen-Friedenreich disaccharide of Formula XXVII and 28 mg (0.16 mmols) of mTEGSH in 5 ml of 16 μM $\text{Cd}(\text{ClO}_4)_2$ (0.09 mmols) was purged with argon for 10 minutes (initial pH 2.9; no pH adjustment was made). To this deaerated solution was quickly added 875 μl of freshly-prepared 50 mM NaHTe. The reaction solution immediately turned brown. The ratio of reactants was 4.9 RSH (1 TfSH: 3 TEGSH) : 2 Cd^{2+} : 1 Te^{2-} . When heating to reflux commenced in the open air, the color of the solution changed to bright-yellow. After 42 hours the reaction was cooled and purified on Centriplus ultrafiltration filter with MWCO 50KDa. The luminescence of the mixed Tf-TEG-CdTe quantum dots was brilliant green. The solution was lyophilized, redissolved in D₂O and analyzed by NMR. The NMR is shown in Figure 15c. The Tf-TEG-CdTe quantum dots were understood to have the form illustrated in Figure 15bb.




Figure 15c. NMR spectra in D_2O of hybrid T_7 -mTEG CdTe QDs.

Preparation of mPEG2000-CdTe QDs via Self-Assembly in Aqueous Solution⁵




Figure 15cc

[00129] A solution of 500 mg (0.25 mmols) of mPEG2000-SH (obtained from SunBio of Anyang City, South Korea, www.sunbio.com) in 8 ml of $16\mu M$ $Cd(ClO_4)_2$. The initial pH of the solution was 3.04. After purging with argon for

10 min a solution (1.33 ml) of freshly prepared 50mM NaHTe was quickly injected under argon. The reaction solution immediately became yellow and it was heated to reflux under open air. After development of luminescence, 50 μ l aliquots were withdrawn at regular intervals. A weak greenish luminescence was observed after 19 hours of reflux. After 42 hours, the reaction solution was red-orange and showed strong yellow luminescence under UV light. The solution was cooled and purified by ultrafiltration on Centriplus-YD50 with MWCO 50KDa, freeze-dried, redissolved in D₂O and analyzed by ¹H and ¹³C NMR. The spectrum of both the free mPEG2000-SH and mPEG2000-CdTe QDs is shown in Figures 15d and 15e. The mPEG2000-CdTe QDs were understood to have the structure illustrated in Figure 15cc.




Figure 5d. ¹H NMR spectrum of mPEG2000-CdTe QDs (bottom) in

comparison to the free mPEG2000-SH thiol (bottom).





Figure 15e. ^{13}C NMR spectrum of mPEG2000-CdTe QDs in comparison to the free mPEG2000-SH thiol.

Preparation of Tf-HEXPEG-MAA-CdTe QDs via Self-Assembly in Aqueous

Solution⁵



[00130] A solution of 37 mg (0.049 mmols) of Tf-HEXPEG-SH ((CH₂-

$\text{CH}_2\text{-O})_6\text{-(CH}_2)_5\text{-SH}$ functionalized Thomsen-Friedenreich disaccharide of Formula XXIVc) and 12 μl of MAA (5 μl /85 μl H_2O) in 1.7 ml of 16 μM $\text{Cd}(\text{ClO}_4)_2$ was first adjusted to pH 11 with 1M NaOH and then purged with argon for 20 min prior to quick injection of 230 μl of freshly prepared 50mM NaHTe. The reaction solution instantly turned light-brown and was set to reflux under open air for 68 hours, purified by ultrafiltration on Centriplus-YD50 (MWCO 50KDa) and lyophilized. The NMR of redissolved crystals of the product in D_2O is shown in Figure 15g. The crystals of the product were understood to be Tf-HEXPEG-MAA-CdTe QDs of the structure shown in Figure 15ee.





Figure 15g. ^1H NMR spectrum of Tf-HEXPEG-MAA-CdTe QDs in D_2O .

Preparation of HO-HEXPEG-MAA-CdTe QDs via Self-Assembly in Aqueous Solution⁵

**Figure 15gg**

[00131] A solution of 19 mg (0.049 mmols) of HEXPEG-SH and 12 μl of MAA (5 μl /85 μl H_2O) in 1.7 ml of 16 μM $\text{Cd}(\text{ClO}_4)_2$ (initial pH 2.43) was adjusted to pH 10 with about 50 μl 1M NaOH, the solution was then purged with argon for 20 min. prior to quick injection of 230 μl of 50mM NaHTe. The solution became light-brown immediately. The solution was heated to reflux under open air for 72 hours, cooled and purified by ultrafiltration on an Amicon ultrafiltration device (MWCO 30KDa), lyophilized, redissolved in D_2O and analyzed by NMR. Figure 15h shows the ^1H NMR spectrum of the functionalized quantum dots. The functionalize quantum dots were understood to be HO-HEXPEG-MAA-CdTe QDs of the structure shown in Figure 15gg.




Figure 15h. ^1H NMR spectrum of HO-HEXPEG-MAA-CdTe QDs in D_2O .

Quantum Yield Determination

[00132] Quantum efficiency was determined on a FluoMax-2 spectrofluorimeter (Jobin Yvon, www.jyhoriba.co.uk) using an excitation wavelength of 490 nm. Spectra were recorded in Starna® 2x10mm quartz cells. Because the photo-physical properties of fluorescein most closely resembled those of the Tf -encapsulated quantum dots (Tf -MAA-CdTe, illustrated in Figure 14tt), we chose this dye as our standard. A solution of fluorescein in 0.1 M NaOH has an absorption maximum at $\lambda_{\text{max}} = 490$ nm and an emission maximum at $\lambda_{\text{max}} = 513$ nm while the Tf -MAA-CdTe quantum dots, illustrated in Figure 14tt, have a first absorption maximum at $\lambda = 460$ nm and emit at $\lambda_{\text{max}} = 520$ nm. Six dilutions each of fluorescein and the Tf -MAA-CdTe quantum dots were prepared with $A_{490} = 0.000, 0.021, 0.033, 0.055, 0.075, 0.100$ and $A_{490} = 0.000, 0.015, 0.023, 0.040, 0.064, 0.087$, respectively. Integrated fluorescence intensity was calculated from

the fully corrected fluorescence spectra. A graph of integrated fluorescence versus absorbance is shown in Figure 16.




Figure 16. Quantum efficiency determination for T₇-MAA-CdTe QDs. Squares: Fluorescein (Aldrich #F245-6) in 0.1M NaOH; Circles: T₇-MAA-CdTe QDs in water.

Linear Regression through origin for Fluorescein:

$$Y = B * X$$

Parameter	Value	Error
B	113.94277	2.53416

R	SD	N	P
0.99695	0.35999	6	<0.0001

Linear Regression through origin for TF-MAA CdTe:

$$Y = B * X$$

Parameter	Value	Error
B	14.45289	0.83938

R	SD	N	P
0.98101	0.09849	6	2.1152E-4

$QE_{QD} = QE_{FL}(B_{QD}/B_{FL}) = 79 \times (14.45/113.94) = 10\%$, where QE_{QD} is quantum efficiency of quantum dots; QE_{FL} is standard quantum efficiency of fluorescein; B_{QD} is the slope for the fluorescein linear fit; B_{FL} is the slope for the quantum dots.

Table 1. Quantum efficiency determination for T_r-MAA-CdTe QDs

Lectin Affinity Chromatography (LAC) of T_r-MAA-CdTe QDs

[00133] Agarose-bound galactose-specific peanut agglutinin (PNA) and mannose/glucose-specific *Pisum sativum* agglutinin (PSA) were purchased from Vector Labs, Burlingame, CA (www.vectorlabs.com).




Figure 17

[00134] Equal amounts (1 mL) of agarose-immobilized PSA and PNA were loaded onto two separate columns and washed with 10 bed volumes of 1x PBS (phosphate buffer saline) at pH 7.4 to wash out the lectin-stabilizing sugars. A 1x PBS solution is obtained by diluting a volume of commercial 10x PBS with 9 volumes of water. Solutions of T_r-MAA-CdTe QDs (illustrated in Figure 14tt) in water (50 μ l) were loaded onto each column and further soaked in with 150 μ l of 1x PBS (see Figure 17A). After 10 minutes, each column was washed with 10 bed volumes of 1x PBS in 1 ml aliquots (see Figure 17B). Each aliquot was compared to the solution of 50 μ l T_r-MAA-CdTe QDs in 1ml 1x PBS by UV-Vis spectroscopy. Figure 18 shows UV-Vis absorption spectra of some of the collected aliquots. No QDs were detected in the eluent from the PNA column in any of the 10x1ml aliquots while elution of QDs from the PSA column appeared to be complete in the first 1ml aliquot. Washing of the PNA column with several

1 ml aliquots of 200mM galactose appeared to competitively displace quantum dots bound to the PNA, thus indicating reversibility of the binding (see Figure 17C). Figure 19 shows UV-Vis spectra of the first three aliquots of the galactose elutions; these appeared to completely displace the quantum dots from the column.




Figure 18. (A) 50 μ l Tf-MAA-CdTe QDs eluted from galactose-binding PNA-agarose AC column with 1 ml PBS buffer pH 7.4; (B) 50 μ l Tf-MAA-CdTe QDs eluted from mannose-binding PSA-agarose AC column with 1 ml PBS at pH 7.4; (C) 50 μ l Tf-MAA-CdTe dissolved in 1 ml PBS at pH 7.4.




Figure 19. (A) 50 μ l Tf-MAA-CdTe QDs eluted from galactose-binding PNA-agarose AC column with 1 ml 200 mM D-Galactose in PBS at pH 7.4; (B) Same, second elution with 1 ml 200 mM D-Galactose in PBS at pH 7.4 ; (C) Same, third elution with 1 ml 200 mM D-Galactose in PBS at pH 7.4.





Figure 20. The absorption and emission spectra of T₇-MAA-CdTe QDs ($\lambda_{\text{max}}=460$ nm). (The sharp peak at 490nm in the emission spectrum is the Raleigh scattering peak at the excitation wavelength).

Transmission electron micrographs of hybrid T₇-MAA CdTe QDs (illustrated in Figure 14tt) whose UV-Vis spectrum is shown in Figure 20.



Figure 21. Transmission electron microscopy (TEM) images of (a) control; (b) T_r-MAA-xs CdTe QDs alone; (c) 15 min after addition of peanut agglutinin (PNA).




Histogram and Probabilities for GR1:

Mean	SD	Maximum	Minimum	Size
4.63422	3.0228	21	2	263

Histogram and Probabilities for GR1-PNA:

Mean	SD	Maximum	Minimum	Size
11.22182	22.56028	146	2	110



Lectin Affinity Chromatography (LAC) of T₇-TEG-CdTe QDs

[00135] Agarose-bound galactose-specific peanut agglutinin (PNA) and mannose/glucose-specific *Pisum sativum* agglutinin (PSA) were purchased from Vector Labs, Burlingame, CA (www.vectorlabs.com).




Figure 23

[00136] Equal amounts (1 mL) of agarose-immobilized PSA and PNA were loaded onto two separate columns and washed with 10 bed volumes of 1x PBS at pH 7.4 to wash out the lectin-stabilizing sugars. Solutions of T_r-TEG-CdTe QDs (illustrated in Figure 15bb) in water (50 µl) were loaded onto each column and further soaked in with 150 µl of 1x PBS (see Figure 23A). After 10 minutes, each column was washed with 10 bed volumes of 1x PBS in 1 ml aliquots (see Figure 23B). Each aliquot was compared to the solution of 50µl T_r-TEG-CdTe QDs in 1 ml 1x PBS by UV-Vis spectroscopy. No QDs were detected in the eluent from the PNA column in any of the 10x1ml aliquots while elution of QDs from the PSA column appeared to be complete in the first 1 ml aliquot. Washing of the PNA column with several 1 ml aliquots of 200 mM galactose appeared to competitively displace quantum dots bound to the PNA, thus indicating reversibility of the binding (see Figure 23C). The competitive displacement of the quantum dots was noted by observing the luminescence of the eluent.

[00137] Preliminary results suggested that Thomsen-Friedenreich-functionalized quantum dots bind to endothelial cells which are thought to express galectin-3, a carbohydrate-binding protein that binds strongly to the Thomsen-Friedenreich antigen. Initial results of a first experiment indicated that T_r-MAA-CdTe quantum dots (Thomsen-Friedenreich- and mercaptoacetic acid-functionalized cadmium-telluride hybrid quantum dots, illustrated in Figure 14tt), bound to endothelial cells and also bound to other cell types. Results of a second experiment suggested that Tf-TEG-CdTe quantum dots (Thomsen-Friedenreich-

and triethylene-glycol-functionalized cadmium-telluride quantum dots, illustrated in Figure 15bb) selectively bound to endothelial cells. The Tf-TEG-CdTe quantum dots appeared to bind to both resting and activated endothelial cells. Thus, it appeared that the Tf-TEG-CdTe quantum dots exhibited greater cell binding specificity than the T_r-MAA-CdTe quantum dots. It was hypothesized that the charge associated with a mercaptoacetic acid group in solution results in binding of T_r-MAA-CdTe quantum dots to certain cells which exhibit little or no binding with the Thomsen-Friedenreich antigen itself. By contrast, the mercapto triethylene glycol group does not have an associated charge when in solution. As a result, binding of T_r-TEG-CdTe quantum dots may be determined primarily or exclusively by the strength of the binding of a cell with the Thomsen-Friedenreich antigen itself.

[00138] The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. All examples presented are representative and non-limiting. The above-described embodiments of the invention may be modified or varied, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.

References:

- (1) Svarovsky, S. A.; Barchi, J. J. *Carbohydr. Res.* **2003** 328, 1925-1935.
- (2) Wang, Y. A.; Li, J. J.; Chen, H. Y.; Peng, X. G. *J. Am. Chem. Soc.* **2002**, 124, 2293.
- (3) Aldana, J.; Wang, Y. A.; Peng, X. *J. Am. Chem. Soc.* **2001**, 123, 8844.
- (4) Tamura, J.; Fukuda, M.; Tanaka, J.; Kawa, M. *J. Carbohydr. Chem.* **2002**, 21, 445.
- (5) Gaponik, N.; Talapin, D. V.; Rogach, A. L.; Hoppe, K.; Shevchenko, E. V.; Kornowski, A.; Eychmuller, A.; Weller, H. *J. Phys. Chem. B* **2002**, 106, 7177.

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- ✓ GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

WHAT IS CLAIMED IS:

1. A biofunctionalized quantum dot, comprising:
a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface;
a mercaptoalkanoic acid linked to the surface; and
a biofunctional group linked to the surface.
2. The biofunctionalized quantum dot of claim 1,
the ratio of mercaptoalkanoic acid molecules to biofunctional group molecules linked to the surface being in the range of from about 1:1 to about 5:1.
3. The biofunctionalized quantum dot of claim 1,
the mercaptoalkanoic acid not comprising mercaptosuccinic acid.
4. The biofunctionalized quantum dot of claim 1,
the mercaptoalkanoic acid having exactly one carboxyl group and comprising less than seven carbon atoms.
5. The biofunctionalized quantum dot of claim 1,
the mercaptoalkanoic acid comprising mercaptoacetic acid.
6. The biofunctionalized quantum dot of claim 1, further comprising:
a shell layer overcoating the nanocrystalline core.
7. The biofunctionalized quantum dot of claim 6,
the shell layer comprising cadmium sulfide and
the nanocrystalline core comprising cadmium telluride.
8. The biofunctionalized quantum dot of claim 6,
the shell layer comprising cadmium sulfide and
the nanocrystalline core comprising cadmium selenide.

9. The biofunctionalized quantum dot of claim 6, the shell layer comprising mercury sulfide and the nanocrystalline core comprising mercury telluride.
10. The biofunctionalized quantum dot of claim 6, the shell layer comprising mercury sulfide and the nanocrystalline core comprising mercury selenide.
11. The biofunctionalized quantum dot of claim 1, the biofunctional group being a saccharide.
12. The biofunctionalized quantum dot of claim 11, the saccharide not comprising mannose or dextran.
13. The biofunctionalized quantum dot of claim 11, the saccharide being a tumor-associated carbohydrate antigen.
14. The biofunctionalized quantum dot of claim 11, the saccharide being Thomsen-Friedenreich disaccharide.
15. The biofunctionalized quantum dot of claim 11, the saccharide being linked to a sulfur atom; and the sulfur atom being linked to the surface of the nanocrystalline core.
16. The biofunctionalized quantum dot of claim 11, the saccharide being linked to a linking group; the linking group being linked to a sulfur atom; and the sulfur atom being linked to the surface of the nanocrystalline core.
17. The biofunctionalized quantum dot of claim 16, the linking group comprising a carbon atom.
18. The biofunctionalized quantum dot of claim 1,

the biofunctional group having a molecular weight greater than a molecular weight of the mercaptoalkanoic acid.

19. The biofunctionalized quantum dot of claim 1,
the biofunctional group having a molecular volume greater than a molecular volume of the mercaptoalkanoic acid.


20. A biofunctionalized quantum dot, comprising:
a nanocrystalline core exhibiting quantum confinement and having a surface; and
a biofunctional group linked to the surface, wherein
the biofunctionalized quantum dot is stable in aqueous solution under storage in the dark at 4 °C for at least 4 months with respect to luminescence, precipitation, flocculation, and leaching of the biofunctional group.

21. A formulation comprising:
a liquid; and
a biofunctionalized quantum dot, comprising
a nanocrystalline core exhibiting quantum confinement and having a surface,
a mercaptoalkanoic acid linked to the surface, and
a biofunctional group linked to the surface, wherein
the biofunctionalized quantum dot is dissolved or suspended in the liquid
and
the biofunctionalized quantum dot does not precipitate or flocculate.

22. The formulation of claim 21,
the biofunctional group being a saccharide.

23. The formulation of claim 22,
the saccharide being Thomsen-Friedenreich disaccharide.


24. The formulation of claim 22,
the mercaptoalkanoic acid comprising mercaptoacetic acid.
25. A method for producing a biofunctionalized quantum dot, comprising the steps of:
providing a biofunctional group-thiol of Formula III; and



refluxing the biofunctional group-thiol of Formula III with a cadmium salt, a hydrogen-alkali-group VIA element, and a suitable solvent to produce a quantum dot in a solution, wherein

R₁ comprises a carbon atom and
the group VIA element is selected from the group consisting of tellurium and selenium.

26. The method of claim 25,
the suitable solvent comprising water.
27. The method of claim 25,
the suitable solvent comprising N,N-dimethylformamide.
28. The method of claim 25, further comprising the steps of:
reacting a glycoside of Formula I with an alkylthio acid in the presence of a catalyst to produce a thioester of Formula II;





II


debenzylidenating the thioester of Formula II; and

hydrolyzing the thioester of Formula II to produce the biofunctional group-thiol of Formula III, wherein


R₁ comprises a carbon atom and R₂ comprises a carbon atom.

29. The method of claim 25,
the refluxing further comprising refluxing with a mercaptoalkanoic acid.
30. The method of claim 25, wherein
the biofunctional group is a saccharide.
31. The method of claim 30, wherein
the saccharide is Thomsen-Friedenreich disaccharide.
32. The method of claim 25, further comprising the steps of:
purifying the solution; and
drying the purified solution to obtain a biofunctionalized quantum dot preparation.
33. The method of claim 32,
the purifying comprising separating the saccharide-functionalized quantum dot from the remainder of the solution by filtration through an ultrafiltration membrane with a cutoff of about 50 kilodaltons.
34. The method of claim 32, further comprising the step of:
dissolving or suspending the purified and dried biofunctionalized quantum dot preparation in an aqueous solvent.

35. The method of claim 29,
conducting the refluxing for from about 24 to about 48 hours.
36. The method of claim 29,
the mercaptoalkanoic acid being mercaptoacetic acid.
37. The method of claim 36,
the biofunctional group being Thomsen-Friedenreich disaccharide; and
the mercaptoacetic acid and the Thomsen-Friedenreich-thiol being in a
molar ratio of from about 1:1 to about 5:1.
38. A method for producing a biofunctionalized quantum dot, comprising the
steps of:
reacting a glycoside of Formula IV with an alkylthio acid in the presence
of 2,2'-azobisisobutyronitrile in 1,4-dioxane at about 75 °C to produce a thioester
of Formula V;




IV



V

debenzylidinating the thioester of Formula V;
 hydrolyzing the debenzylidinated thioester of Formula V to produce a
 Thomsen-Friedenreich-thiol of Formula VI; and



VI

refluxing the Thomsen-Friedenreich-thiol of Formula VI with cadmium
 perchlorate, mercaptoacetic acid, hydrogen sodium telluride, and a suitable
 solvent, selected from the group consisting of water and N,N-dimethylformamide,
 to produce a Thomsen-Friedenreich-functionalized quantum dot in a solution.

39. The method of claim 38,
 the debenzylidinating comprising the steps of
 treating the thioester of Formula V with aqueous acetic acid at about
 60 °C and
 evaporating to obtain debenzylidinated thioester.
40. The method of claim 38,
 the debenzylidinating comprising the steps of

wavelength and comprising

a nanocrystalline core exhibiting quantum confinement having a surface, and

a biofunctional group linked to the surface;

contacting the biofunctionalized quantum dot with a biological material;

exposing the biological material to light having a wavelength effective to cause the quantum dot to fluoresce; and

imaging the fluorescing quantum dots, wherein

the biofunctional group comprises a saccharide or the quantum dot further comprises a mercaptoalkanoic acid linked to the surface.

44. The method of claim 43, further comprising the step of imaging the fluorescing quantum dot adhered to a secretion of the biological material.

45. The method of claim 43, the biofunctional group being Thomsen-Friedenreich disaccharide.

46. The method of claim 43, further comprising the step of dissolving or suspending the biofunctionalized quantum dot in a biocompatible aqueous solvent.

47. The method of claim 43, the biological material comprising a cell culture.

48. The method of claim 43, the biological material comprising a tissue.

49. The method of claim 43, the contacting comprising injecting the biofunctionalized quantum dot into tissues of a living animal.

50. The method of claim 43, further comprising the step of

using the imaging to identify tissue to which the biofunctional group exhibits high affinity as tissue in a diseased or abnormal state.

51. The method of claim 43,
the diseased or abnormal state being cancerous.
52. A method of medical imaging, comprising the steps of:
providing two types of biofunctionalized quantum dots, each type having a characteristic wavelength distinct from the other types, each quantum dot comprising
a nanocrystalline core exhibiting quantum confinement having a surface, and
a biofunctional group linked to the surface;
each type of quantum dot functionalized with a different antigen or a different set of antigens;
contacting the two types of biofunctionalized quantum dots with a biological material;
exposing the biological material to light having a wavelength effective to cause the quantum dots to fluoresce; and
imaging the fluorescing quantum dots, wherein
the biofunctional group comprises a saccharide or the quantum dot further comprises a mercaptoalkanoic acid linked to the surface.
53. A method of therapy, comprising the steps of:
providing a biofunctionalized quantum dot having a characteristic wavelength and comprising
a nanocrystalline core exhibiting quantum confinement having a surface and
a biofunctional group linked to the surface; and
contacting the biofunctionalized quantum dot with a biological material and thereby treating a disease, wherein
the biofunctional group comprises a saccharide or the quantum dot further

comprises a mercaptoalkanoic acid linked to the surface.

54. The method of claim 53, further comprising
exposing the biological material to light having a wavelength effective to
cause the quantum dots to fluoresce; and
imaging the fluorescing quantum dots.
55. The method of claim 53,
the biofunctional group being an immune-response stimulating group.
56. The method of claim 53,
the biofunctional group being a tumor-associated antigen.
57. The method of claim 53,
the biofunctional group being Thomsen-Friedenreich disaccharide.
58. The method of claim 53, further comprising the step of
dissolving or suspending the biofunctionalized quantum dot in a
biocompatible aqueous solvent.
59. The method of claim 53,
the contacting comprising injecting the biofunctionalized quantum dot into
tissues of a living animal.
60. The method of claim 53, wherein
the disease is cancer.
61. The method of claim 53, wherein
the quantum dot further comprises a therapeutic agent linked to the
surface.
62. The method of claim 53, wherein
a shell layer or the nanocrystalline shell comprises a therapeutic agent.

63. A biofunctionalized quantum dot coated device, comprising
a device adapted for contact with a biological material and
having a device surface;
biofunctionalized quantum dots comprising
a nanocrystalline core exhibiting quantum confinement having a
surface and
a biofunctional group linked to the nanocrystalline core surface; and
the biofunctionalized quantum dots linked to the device surface to form a
coating on the device, wherein
the biofunctional group comprises a saccharide or the quantum dot further
comprises a mercaptoalkanoic acid linked to the nanocrystalline core surface.
64. A cell-quantum dot complex, comprising:
a biofunctionalized quantum dot comprising
a nanocrystalline core exhibiting quantum confinement having a
surface and
a biofunctional group linked to the nanocrystalline core surface; and
a cell, wherein
the biofunctional group is linked to the cell and
the biofunctional group comprises a saccharide or the quantum dot further
comprises a mercaptoalkanoic acid linked to the nanocrystalline core surface.
65. The complex of claim 64, wherein
the biofunctionalized quantum dot further comprises a mercaptoalkanoic
acid linked to the nanocrystalline core surface.
66. The complex of claim 64,
the biofunctional group being Thomsen-Friedenreich disaccharide.
67. The biofunctionalized quantum dot of claim 14,
that is substantially retained by agarose-bound galactose specific
peanut agglutinin and


that is not substantially retained by agarose-bound
mannose/glucose-specific *Pisum sativum* agglutinin.

68. Omitted.

69. The biofunctionalized quantum dot of claim 1, wherein
the mercaptoalkanoic acid is not linked to the surface through a zinc atom
and
the biofunctional group is not linked to the surface through a zinc atom.

70. The biofunctionalized quantum dot of claim 1, wherein
the mercaptoalkanoic acid is not linked to the surface through a group VA
or VIA element which is present in the nanocrystalline core and
the biofunctional group is not linked to the surface through a group VA or
VIA element which is present in the nanocrystalline core.

71. An ethylene-glycol-functionalized quantum dot, comprising:
 a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface;
 a linking group; and
 an ethylene glycol unit linked to the surface through the linking group,
 wherein
 the linking group does not comprise zinc.
72. An ethylene-glycol-functionalized quantum dot of claim 71, wherein
 the linking group does not comprise a group VA or VIA element which is present in the nanocrystalline core.
73. The ethylene-glycol-functionalized quantum dot of claim 71, comprising
 a group of formula XI, comprising a sulfur atom, wherein
 the sulfur atom is linked to the surface.




XI

74. The ethylene-glycol-functionalized quantum dot of claim 73, wherein
 the nanocrystalline core comprises cadmium telluride.
75. An ethylene-glycol- and bio-functionalized quantum dot, comprising:
 a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface;
 a linking group;
 an ethylene glycol unit linked to the surface through the linking group;
 a biofunctional group, linked to the surface, wherein
 the linking group does not comprise zinc.

76. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, wherein
the linking group does not comprise a group VA or VIA element which is present in the nanocrystalline core.
77. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, further comprising:
a substantially zinc-free shell layer overcoating the nanocrystalline core.
78. The ethylene-glycol- and bio-functionalized quantum dot of claim 77, the shell layer comprising cadmium sulfide; and
the nanocrystalline core selected from the group consisting of cadmium telluride and cadmium selenide.
79. The ethylene-glycol- and bio-functionalized quantum dot of claim 77, the shell layer comprising mercury sulfide; and
the nanocrystalline core selected from the group consisting of mercury telluride and mercury selenide.
80. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, wherein
the biofunctional group comprises at least one biofunctional unit which is not a peptide.
81. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, the biofunctional group comprising a biofunctional unit selected from the group consisting of a monosaccharide unit, a mononucleoside unit, a mononucleotide unit, a mono peptide unit, a glycopeptide unit, a lipid unit, and a glycolipid unit.
82. The ethylene-glycol- and bio-functionalized quantum dot of claim 81, the biofunctional group comprising at least one monosaccharide unit.

83. The ethylene-glycol- and bio-functionalized quantum dot of claim 81, the biofunctional group not comprising mannose or dextran.
84. The ethylene-glycol- and bio-functionalized quantum dot of claim 82, the biofunctional group comprising at least one tumor-associated carbohydrate antigen.
85. The ethylene-glycol- and bio-functionalized quantum dot of claim 82, the biofunctional group comprising Thomsen-Friedenreich disaccharide.
86. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, comprising
an ethylene glycol thiol of Formula XIIIb comprising a sulfur atom, wherein



XIIIb

the sulfur atom is linked to the surface,
p is a positive integer, and
q is an integer of at least two.

87. The ethylene-glycol- and bio-functionalized quantum dot of claim 86, wherein
p is two and
q is two.
88. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, comprising
a branched linked chain comprising the ethylene glycol unit.

89. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, comprising

a carboxylic acid unit linked to the surface.

90. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, further comprising

at least one ethylene-glycol-containing linked chain; and

at least one biofunctional-group-containing linked chain, wherein

the ratio of ethylene-glycol-containing linked chains to biofunctional-group-containing linked chains is in the range of from about 1:1 to about 5:1.

91. The ethylene-glycol- and bio-functionalized quantum dot of claim 90, wherein

the ratio of ethylene-glycol-containing linked chains to biofunctional-group-containing linked chains is about 1:3.

92. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, further comprising:

an ethylene-glycol-containing linked chain; and

a biofunctional-group-containing linked chain, wherein

the ethylene-glycol-containing linked chain does not comprise a biofunctional group, and


the biofunctional-group-containing linked chain does not comprise an ethylene glycol unit.

93. The ethylene-glycol- and bio-functionalized quantum dot of claim 92, wherein

the ethylene-glycol-containing linked chain comprises from 3 to 6 ethylene glycol units.

94. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, further comprising:


an ethylene-glycol-containing linked chain of formula XI,
 the sulfur atom of the ethylene-glycol-containing linked chain of formula XI linked to the surface;



XI

a biofunctional-group-containing linked chain of formula XXVII,
 comprising a Thomsen-Friedenreich disaccharide as the biological group and five carbon atoms and a sulfur atom;

the sulfur atom of the biofunctional-group-containing linked chain of formula XXVIIa being linked to the surface.



XXVIIa

95. The ethylene-glycol- and bio-functionalized quantum dot of claim 94,
 the nanocrystalline core consisting of cadmium telluride.
96. The ethylene-glycol- and bio-functionalized quantum dot of claim 95,
 that is substantially retained by agarose-bound galactose specific
 peanut agglutinin and
 that is not substantially retained by agarose-bound
 mannose/glucose-specific *Pisum sativum* agglutinin.
97. The ethylene-glycol- and bio-functionalized quantum dot of claim 95,

that exhibits binding with endothelial cells.

98. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, comprising:

a biofunctional-group-containing linked chain, wherein

the ethylene glycol unit is part of the biofunctional-group-containing linked chain and

the biofunctional group is part of the biofunctional-group-containing linked chain.


99. The ethylene-glycol- and bio-functionalized quantum dot of claim 75, further comprising:

a biofunctional-group-containing linked chain of Formula XXVIIb,

comprising a Thomsen-Friedenreich disaccharide as the biological group and

comprising six ethylene glycol units, five carbon atoms, and a sulfur atom; and

the sulfur atom of the biofunctional-group-containing linked chain of Formula XXVIIb linked to the surface.




XXVIIb

100. The method of claim 107, wherein

the refluxing further comprises refluxing with a luminescence promoter selected from the group consisting of mercaptoacetic acid and an ethylene glycol

thiol,

the ethylene glycol thiol is of Formula XIII,



XIII

p is a positive integer, and

q is an integer of at least two.

101. The method of claim 100, wherein

p is two and

q is two.

102. A formulation comprising:

a liquid; and

an ethylene-glycol- and bio-functionalized quantum dot, comprising

a nanocrystalline core exhibiting quantum confinement and having
a band gap and a surface,

a linking group,

an ethylene glycol unit linked to the surface through the linking group;
and

a biofunctional group linked to the surface, wherein

the linking group does not comprise zinc,

the ethylene-glycol- and bio-functionalized quantum dot is dissolved or
suspended in the liquid.


103. The formulation of claim 102, wherein

the ethylene-glycol- and bio-functionalized quantum dot essentially does
not precipitate or flocculate.

104. The ethylene-glycol- and bio-functionalized quantum dot of claim 102,

the biofunctional group comprising a biofunctional unit selected from the group consisting of a monosaccharide unit, a mononucleoside unit, a mononucleotide unit, a mono peptide unit, a glycopeptide unit, a lipid unit, and a glycolipid unit.


105. The formulation of claim 104,
the biofunctional group consisting of at least one monosaccharide unit.
106. The formulation of claim 105,
the biofunctional group comprising Thomsen-Friedenreich disaccharide.
107. A method for producing an ethylene-glycol-functionalized quantum dot, comprising the steps of:
providing an ethylene-glycol thiol, comprising an ethylene glycol unit;
refluxing the ethylene-glycol thiol with a group IIB element salt, a hydrogen-alkali-group VIA element compound, and a suitable solvent to produce a quantum dot in a solution.
108. The method of claim 107, wherein
the ethylene glycol thiol is of Formula XIII, wherein



XIII

p is a positive integer and
q is an integer of at least two.


109. The method of claim 108, wherein:
the ethylene-glycol thiol is of Formula XIV.




XIV

110. The method of claim 108, wherein
the group IIB element salt is cadmium perchlorate and
the hydrogen-alkali-group VIA element compound is hydrogen sodium telluride.
111. A method for producing an ethylene-glycol- and bio-functionalized quantum dot, comprising the steps of:
providing a biofunctional group-thiol, comprising a biofunctional unit;
providing an ethylene glycol unit; and
refluxing the biofunctional group-thiol and the ethylene glycol unit with a group IIB element salt, a hydrogen-alkali-group VIA element compound, and a suitable solvent to produce a quantum dot in a solution.
112. The method of claim 111,
the biofunctional unit selected from the group consisting of a monosaccharide unit, a mononucleoside unit, a mononucleotide unit, a mono-peptide unit, a glycopeptide unit, a lipid unit, and a glycolipid unit.
113. The method of claim 112,
the biofunctional unit is a monosaccharide unit.
114. The method of claim 113,
the biofunctional group comprising Thomsen-Friedenreich disaccharide.
115. The method of claim 111,
the suitable solvent selected from the group consisting of water and N,N-dimethylformamide.

116. The method of claim 111, further comprising the steps of:
purifying the solution; and
drying the purified solution.
117. The method of claim 116,
the purifying comprising separating the bio-functionalized quantum dot
from the remainder of the solution by filtration through an ultrafiltration filter with
a cutoff of about 50 kilodaltons.
118. The method of claim 116, further comprising the step of:
dissolving or suspending the purified and dried ethylene-glycol- and bio-
functionalized quantum dot preparation in an aqueous solvent.
119. The method of claim 111,
conducting the refluxing for from about 6 to about 170 hours.
120. The method of claim 119,
conducting the refluxing for about 42 hours.
121. The method of claim 111, further comprising the steps of:
reacting a glycoside of Formula XVIII with an alkylthio acid in the
presence of a catalyst to produce an acetylated, benzylidenated biofunctional
group thiol of Formula XIX;




debenzylidenating the thioester of Formula XIX; and
 hydrolyzing the thioester of Formula XIX to produce the biofunctional
 group-thiol of Formula XVb, wherein



R_{12} comprises a carbon atom and R_{13} comprises a carbon atom.

122. The method of claim 121, wherein:
 the refluxing further comprises refluxing with an ethylene glycol thiol of
 Formula XIII,



XIII

p is a positive integer, and
 q is an integer of at least two.

123. The method of claim 122, wherein:
 the group IIB element salt is cadmium perchlorate,
 the hydrogen-alkali-group VIA element compound is hydrogen sodium
 telluride,
 p is two,
 q is two, and
 the suitable solvent is selected from the group consisting of water and
 N,N-dimethylformamide.

124. The method of claim 122,
 the ethylene glycol thiol of Formula XIII and the biofunctional group thiol


in a ratio of from about 1:1 to about 5:1.

125. The method of claim 124,


the ethylene glycol thiol of Formula XIII and the biofunctional group thiol
in a ratio of about 3:1.

126. The method of claim 123, further comprising the steps of:

reacting a glycoside comprising Thomsen-Friedenreich disaccharide of
Formula XXV with mercaptoacetic acid in the presence of 2,2'-
azobisisobutyronitrile in 1,4-dioxane at about 75 °C and quenching with
cyclohexane to produce a thioester of Formula XXVI;



XXV




XXVI

debenzylidinating the thioester of Formula XXVI;


hydrolyzing the debenzylidinated thioester of Formula XXVI to produce a

biofunctional-group thiol of Formula XXVII.




XXVII

127. The method of claim 126,
the debenzylidinating comprising the steps of
treating the thioester of Formula XXVI with aqueous acetic acid at
about 45 °C and
evaporating to obtain debenzylidinated thioester.
128. The method of claim 126,
the debenzylidinating comprising the steps of
treating the thioester of Formula XXVI with acetyl chloride in
methanol,
adding pyridine to the thioester of Formula XXVI with acetyl chloride
in methanol for quenching the reaction, and
evaporating to obtain debenzylidinated thioester.
129. The method of claim 126,
the hydrolyzing comprising the step of
treating the debenzylidinated thioester with sodium methoxide in methanol
to produce the Thomsen-Friedenreich-thiol of Formula XXVII.




XXVII

130. The method of claim 126,
 the hydrolyzing comprising the steps of
 treating the debenzylidinated thioester with sodium methoxide in methanol
 while bubbling air through the debenzylidinated thioester, sodium methoxide, and
 methanol to produce a Thomsen-Friedenreich-disulfide of Formula XXVIII and




XXVIII

- treating the Thomsen-Friedenreich-disulfide of Formula XXVIII with
 dithiothreitol in water to produce the Thomsen-Friedenreich-thiol of Formula
 XXVII.



XXVII

131. The method of claim 111, wherein
the biofunctional group-thiol comprises a thiol of formula XVIIb,




XVIIb

wherein,

r is a positive integer and


s is an integer of at least two.

132. The method of claim 131, wherein
the biofunctional group-thiol comprises a thiol of formula XVIIb,



XVIIb

133. The method of claim 131, further comprising the steps of
reacting a compound comprising ethylene glycol of Formula XXb




XXb

with a glycoside having azide and a group of Formula XXbb as pendant groups and quenching the reaction with triethylamine to produce a compound of Formula XXIIIb,




XXbb




XXIIIb

treating the compound of Formula XXIIIb with acetic anhydride and a reducing agent to produce a compound of Formula XXIIIc in which the azide group of Formula XXIIIb is replaced with an acetamido group;



XXIIIc

debenzylidenating the compound of Formula XXIIIc; and
hydrolyzing the compound of Formula XXIIIc to produce the
biofunctional-group thiol of Formula XXIVb, wherein



XXIVb

r is a positive integer,

t is zero or a positive integer, and

R₁₄ comprises a carbon atom.

134. The method of claim 133, wherein

the group IIB element salt is cadmium perchlorate,

the hydrogen-alkali-group VIA element compound is hydrogen sodium telluride,

r is six,


t is three,

R₁₄ is methyl,

the glycoside having an azide and a group of Formula XXbb as pendant groups has Formula XXII



XXbb




XXII

the reducing agent is zinc,

the debenzylidenating comprises treatment with acetyl chloride and quenching with pyridine;

the hydrolyzing comprises treatment with sodium methoxide and quenching with ion-exchange resin, and

the biofunctional-group thiol is of Formula XXIVc.




XXIVc

135. The method of claim 133, wherein

the refluxing further comprises refluxing with a luminescence promoter selected from the group consisting of mercaptoacetic acid and an ethylene glycol thiol,

the ethylene glycol thiol is of Formula XIII,



XIII


p is a positive integer, and

q is an integer of at least two.

136. The method of claim 135,
the luminescence promoter and the biofunctional group thiol in a ratio of from
about 1:1 to about 5:1.


137. The method of claim 136,
the luminescence promoter and the biofunctional group thiol in a ratio of about
3:1.

138. The method of claim 111, further comprising the steps of
reacting a polyethylene glycol with sodium hydroxide and a brominated
alkene to produce a compound of Formula XXa;



XXa

reacting the compound of formula XXa with an alkylthio acid in the presence of a
catalyst to produce a compound of Formula XXb, wherein



XXb

31978-201280

r is a positive integer,

t is zero or a positive integer, and

R_{14} comprises a carbon atom.

139. A method of imaging, comprising the steps of:
providing an ethylene-glycol- and bio-functionalized quantum dot having a characteristic wavelength and comprising
a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface,
a linking group,
an ethylene glycol unit linked to the surface through the linking group,
and
a biofunctional group linked to the surface, wherein
the linking group does not comprise zinc,
contacting the ethylene-glycol- and bio-functionalized quantum dot with a biological material;
exposing the biological material to light having a wavelength effective to cause the quantum dot to fluoresce; and
imaging the fluorescing quantum dots.
140. The method of claim 139, further comprising the step of
imaging the fluorescing quantum dot adhered to a secretion of the biological material.
141. The method of claim 139,
the biofunctional group comprising Thomsen-Friedenreich disaccharide.
142. The method of claim 139, further comprising the step of
dissolving or suspending the ethylene-glycol- and bio-functionalized quantum dot in a biocompatible solvent.
143. The method of claim 139,
the biological material comprising a cell culture.
144. The method of claim 139,
the biological material comprising a tissue.

145. The method of claim 139,
the contacting comprising injecting the ethylene-glycol- and bio-functionalized quantum dot into a tissue of a living animal.
146. The method of claim 139, further comprising the step of
using the imaging to identify tissue to which the biofunctional group exhibits high affinity as tissue in a diseased or abnormal state.
147. The method of claim 146,
the diseased or abnormal state being cancerous.
148. A method of medical imaging, comprising the steps of:
providing two types of ethylene-glycol- and bio-functionalized quantum dots, each type having a characteristic wavelength distinct from the other type, each quantum dot comprising
a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface,
a linking group,
an ethylene glycol unit linked to the surface through the linking group,
and
a biofunctional group linked to the surface, wherein
the linking group does not comprise zinc,
each type of quantum dot functionalized with a different antigen or a different set of antigens;
contacting the two types of ethylene-glycol- and bio-functionalized quantum dots with a biological material;
exposing the biological material to light having a wavelength effective to cause the quantum dots to fluoresce; and
imaging the fluorescing quantum dots.
149. A method of therapy, comprising the steps of:
providing a ethylene-glycol- and bio-functionalized quantum dot having a

characteristic wavelength and comprising

a nanocrystalline core exhibiting quantum confinement and having a band gap and a surface,

a linking group,

an ethylene glycol unit linked to the surface through the linking group, and

a biofunctional group linked to the surface, wherein

the linking group does not comprise zinc,

contacting the ethylene-glycol- and bio-functionalized quantum dot with a biological material and thereby treating a disease.

150. The method of claim 149 further comprising

exposing the biological material to light having a wavelength effective to cause the quantum dots to fluoresce; and

imaging the fluorescing quantum dots.

151. The method of claim 149,

the biofunctional group comprising an immune-response stimulating group.

152. The method of claim 149,

the biofunctional group comprising a tumor-associated antigen.

153. The method of claim 149,

the biofunctional group comprising Thomsen-Friedenreich disaccharide.

154. The method of claim 149, further comprising the step of

dissolving or suspending the ethylene-glycol- and bio-functionalized quantum dot in a biocompatible aqueous solvent.

155. The method of claim 149,

the contacting comprising injecting the ethylene-glycol- and bio-functionalized quantum dot into a tissue of a living animal.


156. The method of claim 149, wherein
the disease is cancer.
157. The method of claim 149, wherein
the quantum dot further comprises a therapeutic agent linked to the
surface.
158. The method of claim 149, wherein
a shell layer or the nanocrystalline core comprises a therapeutic agent.
159. A ethylene-glycol- and bio-functionalized quantum dot coated device,
comprising
a device adapted for contact with a biological material and
having a device surface;
ethylene-glycol- and bio-functionalized quantum dots comprising
a nanocrystalline core exhibiting quantum confinement and having a
band gap and a surface,
a linking group,
an ethylene glycol unit linked to the nanocrystalline core surface
through the linking group, and
a biofunctional group linked to the nanocrystalline core surface,
wherein
the linking group does not comprise zinc and
the ethylene-glycol- and bio-functionalized quantum dots are linked to the
device surface to form a coating on the device.
160. A cell-quantum dot complex, comprising:
a cell,
a ethylene-glycol- and bio-functionalized quantum dot comprising
a nanocrystalline core exhibiting quantum confinement and having a

band gap and a surface,
a linking group,
an ethylene glycol unit linked to the nanocrystalline core surface
through the linking group, and
a biofunctional group linked to the nanocrystalline core surface,
wherein
the linking group does not comprise zinc and
the biofunctional group is linked to the cell.

161. The complex of claim 160,
the biofunctional group comprising Thomsen-Friedenreich disaccharide.
162. A biofunctionalized quantum dot, comprising:
a nanocrystalline core exhibiting quantum confinement and having a band
gap and a surface;
a luminescence promoter linked to the surface;
the luminescence promoter selected from the group consisting of an
ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and
a biofunctional group linked to the surface.
163. A biofunctionalized quantum dot, comprising:
a nanocrystalline core exhibiting quantum confinement and having a
surface;
a luminescence promoter linked to the surface;
the luminescence promoter selected from the group consisting of an
ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and
a biofunctional group linked to the surface, wherein
the biofunctionalized quantum dot is stable in aqueous solution under
storage in the dark at 4 °C for at least 4 months with respect to luminescence,
precipitation, flocculation, and leaching of the biofunctional group.
164. A formulation comprising:

a liquid; and
 a biofunctionalized quantum dot, comprising
 a nanocrystalline core exhibiting quantum confinement and having a surface,
 a luminescence promoter linked to the surface;
 the luminescence promoter selected from the group consisting of an ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and
 a biofunctional group linked to the surface, wherein
 the biofunctionalized quantum dot is dissolved or suspended in the liquid
 and
 the biofunctionalized quantum dot does not precipitate or flocculate.

165. A method for producing a biofunctionalized quantum dot, comprising the steps of:
 providing a biofunctional group-thiol of Formula III; and



refluxing the biofunctional group-thiol of Formula III with a group IIB salt, a hydrogen-alkali-group VIA element, and a suitable solvent to produce a quantum dot in a solution, wherein

 R₁ is selected from the group consisting of a carbon atom and an ethylene glycol unit,


 the group IIB element is selected from the group consisting of cadmium and mercury,

 the group VIA element is selected from the group consisting of tellurium and selenium.


166. A method for producing a biofunctionalized quantum dot, comprising the steps of:

 reacting a glycoside of Formula IV with an alkylthio acid in the presence

of 2,2'-azobisisobutyronitrile in 1,4-dioxane at about 75 °C to produce a thioester of Formula V;




IV



V

debenzylidinating the thioester of Formula V;
hydrolyzing the debenzylidinated thioester of Formula V to produce a
Thomsen-Friedenreich-thiol of Formula VI; and



VI

refluxing the Thomsen-Friedenreich-thiol of Formula VI with cadmium perchlorate, a luminescence promoter, hydrogen sodium telluride, and a suitable solvent, selected from the group consisting of water and N,N-dimethylformamide, to produce a Thomsen-Friedenreich-functionalized quantum dot in a solution, wherein

the luminescence promoter is selected from the group consisting of an alkylthio acid, mercaptoacetic acid, and an ethylene glycol unit.

167. A method of medical imaging, comprising the steps of:

providing two types of biofunctionalized quantum dots, each type having a characteristic wavelength distinct from the other types, each quantum dot comprising

a nanocrystalline core exhibiting quantum confinement and having a surface,

a luminescence promoter linked to the surface;

the luminescence promoter selected from the group consisting of an ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and

a biofunctional group linked to the surface;

each type of quantum dot functionalized with a different antigen or a different set of antigens;

contacting the two types of biofunctionalized quantum dots with a biological material;

exposing the biological material to light having a wavelength effective to cause the quantum dots to fluoresce; and

imaging the fluorescing quantum dots, wherein

the biofunctional group comprises a saccharide or the quantum dot further comprises a mercaptoalkanoic acid linked to the surface.

168. A method of therapy, comprising the steps of:

providing a biofunctionalized quantum dot having a characteristic wavelength and comprising

a nanocrystalline core exhibiting quantum confinement and having a surface,

a luminescence promoter linked to the surface;
the luminescence promoter selected from the group consisting of an ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and
a biofunctional group linked to the surface and
contacting the biofunctionalized quantum dot with a biological material and thereby treating a disease, wherein
the biofunctional group comprises a saccharide or the quantum dot further comprises a mercaptoalkanoic acid linked to the surface.

169. A biofunctionalized quantum dot coated device, comprising
a device adapted for contact with a biological material and
having a device surface;
biofunctionalized quantum dots comprising
a nanocrystalline core exhibiting quantum confinement having a surface,
a luminescence promoter linked to the surface,
the luminescence promoter selected from the group consisting of an ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid, and
a biofunctional group linked to the surface and
the biofunctionalized quantum dots linked to the device surface to form a coating on the device, wherein
the biofunctional group comprises a saccharide or the quantum dot further comprises a mercaptoalkanoic acid linked to the surface.

170. A cell-quantum dot complex, comprising:
a biofunctionalized quantum dot comprising
a nanocrystalline core exhibiting quantum confinement and having a surface
a luminescence promoter linked to the surface;
the luminescence promoter selected from the group consisting of an ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and
a biofunctional group linked to the surface; and
a cell, wherein

the biofunctional group is linked to the cell and
the biofunctional group comprises a saccharide or the quantum dot further
comprises a mercaptoalkanoic acid linked to the surface.

171. A method for producing a luminescence-promoter-functionalized quantum dot, comprising the steps of:

providing a luminescence promoter thiol;
the luminescence promoter selected from the group consisting of an
ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid; and
refluxing the luminescence promoter thiol with a group IIB element salt, a
hydrogen-alkali-group VIA element compound, and a suitable solvent to produce
a quantum dot in a solution.

172. A method for producing a luminescence-promoter- and bio-functionalized quantum dot, comprising the steps of:

providing a biofunctional group-thiol, comprising a biofunctional unit;
providing a luminescence promoter; and
refluxing the biofunctional group-thiol and the luminescence promoter
with a group IIB element salt, a hydrogen-alkali-group VIA element compound,
and a suitable solvent to produce a quantum dot in a solution, wherein
the luminescence promoter is selected from the group consisting of an
ethylene glycol unit, an alkylthio acid, and mercaptoacetic acid.

173. The biofunctionalized quantum dot of claim 14,
that binds to endothelial cells.

174. The ethylene-glycol and bio-functionalized quantum dot of claim 85,
that selectively binds to endothelial cells.

175. Omitted.

176. The ethylene-glycol and bio-functionalized quantum dot of claim 85,

that is substantially retained by agarose-bound galactose specific
peanut agglutinin and

that is not substantially retained by agarose-bound
mannose/glucose-specific *Pisum sativum* agglutinin.

177. The ethylene-glycol and bio-functionalized quantum dot of claim 75,
that is stable in aqueous solution under storage at room temperature in
ambient lighting for at least 4 months with respect to luminescence, precipitation,
and flocculation.

ABSTRACT

Bio-functionalized quantum dots include a luminescence-enhancing mercaptoalkanoic acid and/or an ethylene glycol linked to the surface of a nanocrystalline core and a biofunctional group linked to the surface. The bio-functionalized quantum dots are made by an efficient synthesis method. The bio-functionalized quantum dots can be used in imaging or therapy applications.

DCZ/530964




Figure 1

T_f-MAA-CdTe




Figure 2




Figure 3




Figure 4




Figure 5

APPLICATION DATA SHEET

Application Information

Application Number:: Not Yet Assigned
Filing Date:: March 22, 2004
Application Type:: Provisional Application
Subject Matter:: Utility
Suggested Classification::
Suggested Group Art Unit::
CD-ROM or CD-R?::
Number of CD Disks::
Number of Copies of CDs::
Sequence Submission?::
Computer Readable Form (CFR)?::
Number of Copies of CFR::
Title:: CARBOHYDRATE-ENCAPSULATED QUANTUM DOTS FOR BIOLOGICAL IMAGING
Attorney Docket Number:: 31978-201280
Request for Early Publication?::
Request for Non-Publication?::
Suggested Drawing Figure::
Total Drawing Sheets:: 5
Small Entity?:: NO
Latin Name::
Variety Denomination Name::
Petition Included?::
Petition Type::
Licensed US Govt. Agency::
Contract or Grant Numbers::
Secrecy Order in Parent Appl.::

Applicants' Information (Two Inventors)

Applicant Authority Type::	Inventor
Primary Citizenship::	Russian
Country::	Russia
Status::	Full Capacity
Given Name::	Sergei
Middle Name::	A.
Family Name::	SVAROVSKY
Name Suffix::	
City of Residence::	Frederick
State or Province of Residence::	Maryland
Country of Residence::	United States of America
Street of Mailing Address::	1501 W. 10th Street
City of Mailing Address::	Frederick
State or Province of Mailing Address::	Maryland
Country of Mailing Address::	United States of America
Postal or Zip Code of Mailing Address::	21702

Applicant Authority Type::	Inventor
Primary Citizenship::	U.S.A.
Country::	U.S.A.
Status::	Full Capacity
Given Name::	Joseph
Middle Name::	J.
Family Name::	BARCHI
Name Suffix::	Jr.
City of Residence::	Frederick
State or Province of Residence::	Maryland
Country of Residence::	United States of America
Street of Mailing Address::	8418 Aynsley Court
City of Mailing Address::	Frederick
State or Province of Mailing Address::	Maryland
Country of Mailing Address::	United States of America
Postal or Zip Code of Mailing Address::	21702

Correspondence Information

Correspondence Customer Number::	26694
Phone Number::	(202) 344-4000
Fax Number::	(202) 344-8300
E-Mail Address::	magollin@venable.com

Representative Information

Representative Customer Number::	26694
---	--------------

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::

Foreign Priority Information

Country::	Application Number::	Filing Date::	Priority Claimed::

Assignee Information

Assignee Name::	The Government of the United States of America as represented by the Secretary, Department of Health and Human Services
Street of Mailing Address::	6011 Executive Blvd., Suite 325
City of Mailing Address::	Rockville
State or Province of Mailing Address::	Maryland
Country of Mailing Address::	United States of America
Postal or Zip Code of Mailing Address::	20852-3804